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Hippo signaling is an evolutionarily conserved pathway that restricts organ growth
during development and suppresses regeneration in mature organs. Using a highthroughput phenotypic screen, we have identified a potent, non-toxic, and reversible
inhibitor of Hippo signaling. An ATP-competitive inhibitor of Lats kinases, the compound
causes Yap-dependent proliferation of murine supporting cells in the inner ear, murine
cardiomyocytes, and human Müller glia in retinal organoids. The compound promotes
the initial stages of the proliferative regeneration of hair cells, a process thought to be
permanently suppressed in the adult mammalian inner ear. In conjunction with the TriInstitutional Therapeutics Discovery Institute, we have thoroughly characterized the
compound and generated a suite of over 60 derivatives with improved characteristics
such as potency, pharmacokinetics, and specificity. Together, these compounds offer
powerful tools for molecular investigations of development, stem cell biology, and
regeneration; it is even plausible that drugs related to this novel thiazolimine class will
prove useful in therapeutic contexts.
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Chapter 1
Introduction

Hearing and balance disorders plague hundreds of millions of people across the world.
The World Health Organization estimates 466 million people, or 6.1 % of the world’s
population, live with disabling hearing loss1. In the United States, vestibular dysfunction
has been reported in 35 % of individuals over the age of 402. The affected organs lie
within the inner ear, which comprises six patches of sensory epithelia—five of which are
dedicated to the detection of linear and rotational acceleration; the sixth, the cochlea,
decodes complex sounds waves into neural signals, enabling hearing (Fig 1.1A).
Because these organs lack any regenerative capability, damage accumulates over a
lifetime, leading to the ubiquitous problems. Moreover, no therapeutic approach has
been established for these pathologies, so our best solutions thus far involve
preventative measures, coping strategies, and hearing aids. Over the last few decades,
some barriers to mammalian inner-ear regeneration have been elucidated through
investigations into inner ear development and the regeneration of their homologous
organs in non-mammalian vertebrates. Yet much remains to be understood before we
can develop successful therapies.
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Figure 1.1| Overview of the inner ear. (A) The inner ear comprises six patches of
sensory epithelia encased in a fluid-filled bony labyrinth and is located within the
temporal bone. (B) The utricle and saccule lie orthogonal to each other, allowing for
detection of linear acceleration in all directions. (C) The utricle and saccule have two
polarities of hair cells (red) that reverse around the midline and are arrayed in a
hexagonal pattern among supporting cells (green). The hair bundles are loaded by
otoliths, crystals of calcium carbonate. (D) The ampullae of the three semi-circular
canals bear hair cells (red) of a single polarity, and their hair bundles protrude into a
gelatinous mass termed the cupula (yellow). (E) The organ of Corti lies along a tapered
basal membrane that increases in width from the base of the cochlea to its apex. Inner
hair cells (orange) transmit electrical signals to the central nervous system. Outer hair
cells (red) play a role in amplifying and sharpening the signal. The organ of Corti has
several types of supporting cells, defined by their location and function. Image in (A)
was adapted from Retzius, G. Das Gehörorgan der Wirbelthiere. II. Das Gehörorgan der
Reptilien, der Vögel und der Säugethiere
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Section 1.1: The Mammalian Inner Ear
The sensory epithelia of all mammalian hearing and vestibular organs derive from the
otic placode—the anlagen of the inner ear—and thus share two cell types: supporting
cells, which play a homeostatic and architectural role, and mechanosensitive hair cells,
with their eponymous apical tufts of stereociliary bundles arranged in tightly packed
rows of increasing height. Tip links, proteinaceous strings, connect the tips of adjacent
stereocilia: at its upper edge, each tip link is attached through a series of
transmembrane complexes to myosin motors, that mediate fast adaptation. At its lower
end, a tip link is thought to be connected to ion channels, so thus stretching of the tip
links opens the channels, depolarizing the cell (Fig. 1.2). The orientation of stereociliary
rows, in conjunction with their tip link attachments, allows for their coordinated
movement and directional specificity, for deflection in one direction opens ion channels,
causing depolarization, and deflection in the opposite direction reduces the number of
open channels, yielding hyperpolarization3.
The sensory epithelia of the inner ear are arranged in distinct and precise
geometrical patterns that are critical to their functions. All hair cells of the utricle and
saccule, the organs responsible for the detection of linear acceleration, are either
oriented towards or away from the line of reversal roughly at the midline, and are
arrayed in a hexagonal pattern among supporting cells, which in these organs are
considered a uniform type. The tips of the stereocilia are loaded by otoconia, clusters of
calcium carbonate crystals that provide the mass for inertia-mediated activation (Fig.
1.1B,C). The hair bundles in each of the three ampulae of the semi-circular canal, the
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Figure 1.2| Hair bundles activate in response to unipolar movement. The stereocilia
of hair cells are arranged in rows of increasing height, with tip links connecting the tops
of each. The lower end of the tip links is embedded in ion channels, so when the
Figure
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allowing divalent ions to flow through and depolarize the hair cells. Deflection in the
opposite direction causes hyperpolarization, and deflection orthogonal to the apical
surface of the hair cell has no effect.
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organs responsible for detecting rotational acceleration, are all oriented in a common
direction. The long hair bundles are embedded in a gelatinous mass, called the cupula,
that deflects upon inertial movement of the endolymph within the canals (Fig. 1.1D).
Again the result is depolarization for motion in one direction and hyperpolarization in the
other.4
The cochlea, the organ that processes sound, has the most geometrically
intricate organization. The sensory portion of the cochlea, known as the organ of Corti,
lies upon a basilar membrane of tapering width from the base to the apex, a key
component of its tonotopic gradient. The tunnel of Corti separates the two types of
cochlear hair cells, all of which have their bundles’ short rows medially and tall rows
laterally. These receptors lie among several classes of supporting cells, defined by their
architectural as well as functional roles. Lateral to the tunnel are three parallel rows of
outer hair cells, which are innervated primarily by efferent nerves, and play a role in
amplification and frequency resolution through an active process. These cells display
both depolarization-dependent cytoskeletal contraction and active motion of their
bundles. In contrast, inner hair cells, medial to the tunnel, are innervated by afferent
nerves and thus propagate responses to the central nervous system (Fig. 1.1E)5.
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Section 1.2: Inner Ear Regeneration in Non-Mammalian Vertebrates
Hair cell-based organs in several non-mammalian vertebrates regenerate throughout
their lifetimes. Two models of note are the avian cochlea (basilar papilla) and the
zebrafish lateral line. The latter, which comprises small patches of hair cells and
supporting cells—the neuromasts—distributed longitudinally across the surface of the
body, measures motion of the surrounding fluid for both during normal movement and in
the presence of prey or predators. As in the mammalian utricle and saccule, equal
numbers of hair cells face in the rostral and caudal directions, permitting bi-directional
sensitivity. Studies of these organs in development and regeneration have shed much
light on the high-level processes, as well as the common and the distinct pathways
involved.
The regenerative process in the avian cochlea involves two phases. An early
wave of transdifferentiation, or direct conversion of supporting cells into hair cells, yields
some new hair cells at the cost of supporting cells. To further enable regeneration,
supporting cells adjacent to the site of damage undergo proliferation, yielding daughter
cells that can either differentiate into hair cells or remain supporting cells, thus
preserving the ratio of the cell types (Fig. 1.3A)6. After damage, supporting cells in the
zebrafish neuromasts always undergo division before generating two new, oppositely
oriented hair cells, thereby conserving the balance of vector sensitivity. Supporting cells
also divide symmetrically to replenish their own number (Fig. 1.3B)7.
From these studies and others, it has become clear that the two key processes
involved are transdifferentiation and proliferation of supporting cells. Various classical
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Figure 1.3| Hair cell regeneration in non-mammalian vertebrates. (A) In the avian
cochlea (basilar papilla) hair cells regenerate throughout the organism’s lifespan. This
process involves two main programs: (1) an early wave of transdifferentiation, direct
conversion of adjacent supporting cells into hair cells; (2/3) proliferation of supporting
cells, either symmetrically, replenishing the supporting cell population, or
asymmetrically, yielding one daughter hair cell and one supporting cell. (B) The
neuromast of zebrafish is surrounded by mantle cells (purple) and have hair cells (red)
of two polarities arrayed amongst supporting cells (green). When hair cells die, a nearby
supporting cell undergoes division, yielding two hair cells of opposite polarity.
Supporting cells also undergo division to replenish the supporting cell population.
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signaling paradigms underpin each. Both in development and regeneration,
transdifferentiation is mediated primarily through canonical Notch signaling, an ancient
short-range communication system. This process culminates in the activation of
transcription factors that are necessary for hair cell differentiation, such as Atoh1 and
Pou4F3. Several pathways have been implicated in control of supporting cell
proliferation during regeneration, including Fgf, Wnt, Egf, and Igf signaling4,8.

Section 1.3: Lack of Inner Ear Regeneration in Mammals
In contrast to the lifelong regenerative capacity of non-mammalian vertebrates,
functional hair cell regeneration is largely absent in mammals. In the adult mammalian
utricle, it has been shown that a modest number of hair cells regenerates after total
ablation. However, the new hair cells are predominantly the result of transdifferentiation,
and it is unclear whether there is any significant functional recovery. Although this is a
meager response, it lies in stark contrast to the total inability of the mammalian cochlea
to yield any regenerative response4.
One typical explanation for why the mammalian cochlea does not regenerate is
that, in contrast to its regenerative homologues, it has a drastically more complex
architecture, thought to enable our higher range of frequency detection8. This reasoning
applies less well to the vestibular organs, which are more similar in their organization to
the avian cochlea and zebrafish neuromast. It has been argued that in the vestibular
system, proliferation of supporting cells is impeded by rings of F-actin and E-cadherin
junctions that accumulate around the cells as the organ ages9; this does not occur in the
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regenerative systems. These observations might equally represent a down-stream
effect due to a dearth of proliferation, however and not a primary cause. No functional
evidence has been generated in support of this hypothesis.
More is known about the molecular roadblocks preventing regeneration. In the
cochlea, transdifferentiation is completely absent after damage. In the regenerative
homologues, it is known that Notch-mediated signaling plays a key role. However, in the
adult mammalian cochlea, Notch-responsive genes are expressed at very low levels,
and although some components are upregulated after damage, Notch inhibition in this
context fails to drive significant generation of new hair cells. It is unknown how the
Notch responsiveness of these supporting cells is kept low8,10. In the adult mammalian
utricle new hair cells can arise by transdifferentiation throughout an organism’s lifespan,
although it is unclear how robust the physiological recovery is. In accord with the
utricle’s slightly stronger regenerative capacity, activation of Notch signaling in
supporting cells after hair cell ablation upregulates Atoh1 expression, an early marker of
hair cell differentiation, and a subset of the cells express Myo7a, a marker of mature
hair cells4.
Because it is thought that cell division is a key limiting step in the regenerative
response, anti-proliferative programs have also been an area of intense focus. Wnt
signaling has been shown to drive supporting cell proliferation in both the developing
utricle and cochlea. However, both organs become refractory to Wnt activation as they
age. Several of the cyclin-dependent kinase inhibitors (CDKIs) have also been shown to
play critical roles in maintaining the post-mitotic status of the cochlea: p19Ink4d,
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p21Cip1, p27Kip1, Rb1, and Rbl2. In the utricle, Rb1 has been demonstrated to impede
proliferation, but p19Ink4d and p21Cip1 appear to play no role4,8,10.

Section 1.4: Approaches to Inducing Inner Ear Regeneration
The insights from the investigations highlighted above have directed researchers into
two main avenues of inducing hair cell regeneration. The first, and more thoroughly
studied goal, is that of inducing supporting cell transdifferentiation. Although much more
remains to be investigated, several approaches have demonstrated its potential, as well
as its limitations. The second goal, driving supporting cell proliferation, is thought to be a
key limitation on regeneration, given the natural evidence of its import in bird and
zebrafish homologues, as well as the poor results to date of using only
transdifferenation to drive hair cell regeneration in mammalian systems.
Because hair cell differentiation across these many systems, during both
development and regeneration, is Notch-mediated, many groups have utilized gammasecretase inhibitors in attempts to augment this process in the adult mammalian
systems. Within a few days after birth, the cochlea down-regulates its Notch ligands and
becomes insensitive to inhibition. However, although there is not complete consensus,
some groups report that after damage, the cochlea can upregulate some of the Notch
program. In support of this hypothesis, gamma-secretase inhibition applied to noisedamaged mice increased the number of outer hair cells, but only at the base of the
cochlea. Although there was a notable, but small, physiological recovery at the lowest
frequencies, the overall recovery was minimal at best. Application of a different gamma-
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secretase inhibitor after damage led to ectopic hair cells in guinea pigs. No significant
physiological recovery was appreciated10.
Because Notch signaling is still active in the adult vestibular system, the utricle
can form more hair cells after gamma-secretase treatment in vitro. The preponderance
of this work has been done in explant culture systems and varies in details of the
results: how many new hair cells, the extent of their maturation, and what region of the
utricle are new hair cells found. Moreover, no one has yet demonstrated physiological
recovery in vivo with this approach4.
The other major approach taken for inducing transdifferentiation is to overexpress Atoh1, a transcription factor necessary for—and somewhat sufficient— for the
induction of hair cell formation. In the utricle, virally mediated and transgenic
approaches have been employed, but yielded different results. Adenovirus-mediated
gene delivery improved hair cell regeneration in damaged vestibular organs from adult
rodents; however, physiological recovery was small to absent. The transgenic approach
failed to drive formation of any new hair cells in the adult. In the cochlea, Atoh1 overexpression, either virally or through transgenics, failed to yield new hair cells10.
Several programs, including Wnt signaling and numerous growth factors, have
been shown to augment proliferation during development, but sensitivity to these
perturbations is lost only a few days after birth in both the utricle and the cochlea4,10. In
the utricle, a more drastic measure, over expressing the oncogene N-Myc, did yield
supporting cell proliferation in adult utricle explants in vitro, but all of the cells failed to
progress through G2 or underwent apoptosis after completion of the cell cycle11. Our
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group found that the pioneer transcription factors Sox4 and Sox11 are key in the
proliferation of utricle supporting cell during development; moreover, virally mediated
over-expression in adult explants induced supporting cell proliferation, and a subset of
the resultant cells then differentiated into hair cells12. No approaches have been
demonstrated to induce supporting cell proliferation in the cochlea.

Section 1.5: Hippo-Yap Signaling
A former member of our group, Dr. Ksenia Gnedeva, demonstrated that the Hippo
pathway limits the size of the developing murine utricle, and that the pathway’s downstream target, the Yap-Tead complex is active during—and necessary for—proliferative
regeneration in the neonatal utricle13. These observations suggested that activation of
Yap signaling could engender supporting-cell proliferation in adult tissue.
In view of its fundamental roles in development, proliferation, stem-cell
maintenance, and de-differentiation, Hippo signaling is an inviting target for driving
regeneration14,15. The canonical Hippo pathway is an ancient and highly conserved
signal-transduction cascade that comprises two pairs of core kinases. When proliferation
is inappropriate, Mst1 and Mst2 phosphorylate Lats1 and Lats2; these proteins in turn
phosphorylate the transcriptional co-activator Yap and its homolog Taz, which as a result
are sequestered and degraded in the cytoplasm. When the pathway is inactive, Yap
enters the nucleus, interacts with transcription factors of the Tead family, and initiates cell
division16. Yap signaling integrates a variety of information from the cellular environment,
including biomechanical cues, cell adhesion, cell density, cell polarity, metabolic
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challenges, and signals such as Notch, Wnt, and several GPCR-mediated pathways. The
Hippo cascade is the conduit through which much, but not all, of this information is
integrated into a decision regarding Yap activation17 (Fig. 1.4).
Yap activity has been shown to play a role in the mammalian organs which can
regenerate, such as the liver, lung, intestine, and skin14. Furthermore, increasing Yap
activation in these contexts augments the regenerative response in vivo. Of greater
interest, Yap activation has also been shown to drive regeneration in non-mitotic tissues
such as the heart and retina. After induction of myocardial infarction in adult mice,
treatment with agrin, a secreted protein that activates Yap specifically in that context
through the Dag1 receptor, can cause proliferation of adult mouse cardiomyocytes in vivo.
One month later the ejection fraction of treated mice was identical to that of undamaged
mice18. In retinal tissue, transgenic overexpression of a constitutively active form of Yap
in Müller cells, precursors of photoreceptors, drives cell cycle re-entry, a key missing step
in mammalian retinal regeneration19,20.
Despite the evidence that Yap reactivation offers a uniquely powerful approach for
tissue regeneration, the techniques involved are cumbersome, indirect, or contextspecific21. Transgenic manipulation, viral induction, and GPCR-mediated Yap activation
lack translational value, so due to these shortcomings of available tools, we conducted a
screen for small-molecule activators of Yap. With such a compound, we hoped to test our
original hypothesis that Yap activation in supporting cells of the adult utricle would foster
mitotic hair cell regeneration.
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Figure 1.4| The Hippo Pathway. (A) The core of the Hippo pathway comprises two
pairs of kinases, MST1/2 and LATS1/2, each with co-activators, Sav1 and Mob1
respectively. Despite the relative simplicity of the cascade, there is no specific ligand
and receptor, but instead numerous inputs (“Hippo Regulators”) impinge upon the
cascade at various entry points, yielding an integrative decision regarding Yap
activation. When active, the cascade culminates in the phosphorylation of Yap at
multiple sites, yielding sequestration and degradation of the protein. When the cascade
is inactive, Yap remains unmodified and is free to translocate to the nucleus, where it
binds primarily to members of the Tead family, driving its transcriptomic programs.
Small molecules known to modify the Hippo pathway, and their modes of action, are
indicated in red.
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Section 1.6: Identification of Activators of Yap Signaling
In some monolayer epithelial cultures, increased cell density leads to cytoplasmic
retention and degradation of Yap protein, a process reminiscent of the molecular
mechanism

downstream

of

Hippo-driven

growth

restriction

during

normal

development22,23,24. To seek inhibitors of this process, former members of our group
designed a high-throughput phenotypic screen for compounds that promote nuclear Yap
translocation in confluent human cell cultures. After testing three lines, they chose
MCF 10A mammary epithelial cells, which demonstrated robust negative correlation
between cellular confluence and the fraction of cells with nuclear Yap.
For the small-molecule screen, MCF 10A cells were seeded to achieve dense cultures
in 384-well plates. A single compound was deposited in each well at a concentration of
10 µM. Every plate also included a positive control, sub-confluent cells, and a negative
control, densely cultured cells, both exposed to dimethyl sulfoxide (DMSO) at a
concentration equivalent to that in which the compounds were applied. After 24 hr
incubation, the investigators determined the fraction of the cells with nuclear Yap and
compared that value to the median negative-control value. They also scored the total
number of cells in each well and eliminated toxic substances that decreased the number
by more than one standard deviation in comparison to the dense control cultures.
Nontoxic compounds that increased nuclear Yap by more than one standard deviation in
comparison to the negative control were scored as hits. Owing to the robustness of
contact inhibition in the dense cell cultures, only six of the 140,238 compounds screened
met these criteria and were validated in the secondary screen25.

18

Chapter 2
Methods
Animal care and strains
Experiments were conducted in accordance with the policies of the Institutional Animal
Care and Use Committees of The Rockefeller University, the University of Southern
California, and the Weizmann Institute of Science.
Swiss Webster mice were obtained from Charles River Laboratories. Sox2CreER, aMHC-Cre, and ROSA26-tdTomato mice were obtained from the Jackson
laboratory. Yapfl/fl were provided by Dr. Martin, Baylor College of Medicine.

Chemical libraries
A total of 140,238 different compounds from a library at The Rockefeller University
High-Throughput and Spectroscopy Resource Center were chosen by a quantitative
estimate of drug-likeness score26. The compounds originated in the following
commercially available libraries: ChemDiv (San Diego, CA), Enamine (Monmouth
Junction, NJ), BioFocus (Charles River, Wilmington, MA), ChemBridge (San Diego,
CA), Specs (Zoetermeer, The Netherlands), Life Chemicals (Niagara, Canada), and
AMRI (Albany, NY). Compound stocks were stored in 384-well polypropylene plates at a
final concentration of 5 mM in DMSO at -30 ˚C.
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High-throughput screen for small-molecule activators of nuclear Yap
Three human epithelial cell lines, one human embryonic kidney 293 line (HEK293T),
and two human mammary gland epithelia lines (MDA-MB and MCF 10A), were tested
for the screen. Of the three lines, only MCF 10A cells display a reproducible correlation
between the number of cells seeded and the number of cells adhered after 24h in
culture and thus were selected for the screen.
MCF 10A cells (ATCC CRL-10317) were cultured in a medium comprising
DMEM/F12, 5 % horse serum (Invitrogen 16050-122), 20 ng/L epidermal growth factor
(Millipore GF155), 0.5 mg/L hydrocortisone (Sigma H-0888), 100 ng/L cholera toxin
(Sigma C-8052), 10 mg/L insulin (Sigma I-1882), and antibiotic-antimycotic solution.
Cell cultures reached 100 % confluence at an approximate density of 3·105 cells per
square millimeter.
For the small-molecule screen, chemical-library plates were thawed at room
temperature and 0.1 μL of each compound was placed in a well of a 384-well assay
plates (Greiner Bio-One) containing 10 μL of MCF 10A culture medium (PerkinElmer
Janus with Nanohead). MCF 10A cells were then plated in 40 μL of MCF 10A culture
medium to achieve a final concentration of 10 µM for each compound and 0.25 %
(vol/vol; 35 mM) dimethyl sulfoxide. Negative (100 % confluent) and positive (25 %
confluent) control wells included an identical concentration of the DMSO vehicle.
After 24 hr incubation, the cells were fixed, washed thrice in PBS, and
immunolabeled for Yap. The nuclei were stained with 3 mM 4,6-diamidino2-phenylindole dihydrochloride (DAPI). 10X objective lens on the ImageXpress XLS
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wide-field Micro reader (Molecular Devices, Sunnyvale, CA) with MetaXpress software
(Molecular Devices) were use to automatically image the plates. Using an empty plate
to avoid out-of-focus images, we configured a laser-based autofocus routine for
automatic well-bottom detection. We imaged DAPI and Yap conjugated to Alexa Fluor
488 with filter cubes for respectively DAPI (excitation, 350-400 nm; emission
415-480 nm) and FITC (excitation, 460-505 nm; emission, 510-565 nm). The acquisition
system was configured to image one site per well. After the fluorescence of DAPI had
been used to set the image-based autofocus, the exposure time for each fluorophore
was determined with a negative-control well in which the fluorescence signal was set to
75 % of the camera’s maximal intensity.
An image-segmentation application from MetaXpress software was used to
automatically analyze the images. The number of cells was estimated by selecting an
average size and intensity level above the local background in the DAPI channel.
A built-in translocation module that measured the intensity movement from one
compartment to another was configured to determine the nuclear or cytoplasmic status
of the Yap. These measurements were acquired first for the positive and negative
control wells to determine an arbitrary threshold for the intensity ratio that characterized
nuclear translocation versus cytoplasmic retardation of Yap. The same threshold was
then applied to each well treated with a small-molecule to identify the substances that
increased the number of cells with nuclear Yap without affecting cell survival. Positive
controls were not used to normalize data, but to confirm whether the cells were healthy
and behaving as expected.
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Images were stored in the MDCStore database and analyzed using MetaXpress
software (Molecular Devices). Output data were uploaded and analyzed using the CDD
Vault from Collaborative Drug Discovery (Burlingame, CA).
The compounds showing over 10 % Yap nuclear translocation and over 5,000
cells per field were selected and the corresponding images were checked to verify the
phenotype. To determine half-maximal inhibitory concentrations, the selected
compounds were re-tested in concentration-response experiments by serially diluting by
half for a total of ten dilutions to achieve assay concentrations ranging from 20 µM to
0.03 µM. IC50s values were calculated by CDD software. Six compounds were
confirmed in this secondary screen.

Small-molecule Lats inhibitor
The compound N-(3-benzylthiazol-2(3H)-ylidene)-1H-pyrrolo[2,3-b]pyridine3-carboxamide (CAS number 1424635-83-5), of relative molecular mass 334.4 Da and
herein termed TRULI, was obtained from Enamine LLC (Monmouth Junction, NJ;
catalog number Z730688380).

Dissection and culture of inner-ear sensory epithelia
Internal ears were dissected from mice euthanized with fluothane and placed into icecold Hank’s balanced salt solution (HBSS; Gibco14025-092)12.
Unless indicated otherwise, explanted cultures of the utricle and cochlea were
maintained in an incubator at 37 ˚C in the presence of 5 % CO2 and 95 % O2. The
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complete growth medium comprised Dulbecco's modified Eagle medium with nutrient
mixture F-12 (DMEM/F12) supplemented with 33 mM D-glucose (Sigma G8644),
19 mM NaHCO3 (Sigma S8761), 15 mM HEPES (Sigma H0887), 1 mM glutamine
(Sigma G8540), 5 mM nicotinamide (Sigma N0636), 40 µg/L epidermal growth factor
(Sigma E9644), 20 µg/L fibroblast growth factor (Sigma F5392), insulin-transferrinselenite solution (Sigma 11074547001), and antibiotic-antimycotic solution (Gibco
15240062).
For proliferation assays, utricles were cultured with 10 µM 5-ethynyl2¢-deoxyuridine (EdU) that was detected with click chemistry (Click-iT EdU imaging kit,
Thermo C10340).

Culture of epithelial cells
MCF 10A cells were cultured as described above. HEK293A cells were maintained in
DMEM (Gibco 11965-092), 10 % fetal bovine serum (Sigma F2442), and antibioticantimycotic solution. All cells were incubated at 37 ˚C in the presence of 5 % CO2 and
95 % O2.

Culture of primary cardiomyocytes
Cardiac muscle cells were lineage-traced with tdTomato-fluorescent protein by
intercrossing aMHC-cre mice27, which exhibit highly efficiency recombination in
cardiomyocytes, with ROSA26-tdTomato mice28 that require Cre-mediated
recombination for expression. Both lines were maintained on a C57BL/6 background.
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Neonatal primary cardiac cultures were isolated from P0 (first postnatal day)
pups with a neonatal dissociation kit (Miltenyi Biotec,130-098-373) and homogenizer
(gentleMACS). Cardiac cultures were seeded in gelatin-coated wells coated with 0.1 %
gelatin (G1393, Sigma) in DMEM/F12 medium supplemented with 1% L-glutamine, 1 %
sodium pyruvate, 1 % nonessential amino acids, 1 % penicillin-streptomycin solution,
5 % horse serum, and 10 % fetal bovine serum. After culture in 5 % CO2 for 24 hr at
37 ˚C, the medium was replaced for an additional 72 hr with bovine serum-free medium
containing 0.1 % (vol/vol) DMSO and, for experimental samples, 20 µM TRULI.

Culture of human pluripotent stem cells and retinal organoid
The WTC-11 line of induced pluripotent stem cells (Coriell Institute for Medical
Research, Camden, NJ) was maintained using standard methods. Human retinal
organoids were produced from these cells29. In three independent proliferation assays,
five organoids per experimental condition were sampled after 225-280 d in culture. The
organoids used in the immunoiblot analysis were cultured for 160-178 d.

Immunohistochemistry of murine inner-ear sensory epithelia
Utricles were fixed in 4 % formaldehyde (Thermo 28906) for 1 hr at room temperature
and then blocked for 2 hr at room temperature with 3 % bovine serum albumin (BSA;
Jackson AB 2336846), 3 % normal donkey serum (Sigma-Aldrich D9663), and 0.3 %
Triton X-100 (Sigma 93443), in Tris-buffered saline solution (Thermo 28358).
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The primary antisera—goat anti-Sox2 (R&D AF2018), rabbit anti-myosin 7A
(Proteus 25-6790), mouse anti-Yap (SC-101199), rabbit anti-Sall2 (HPA004162), and
mouse anti-Pou4F3 (SC-81980)—were reconstituted in blocking solution and applied
overnight at 4 ˚C. Samples were washed with phosphate-buffered saline solution
supplemented with 0.1 % Tween 20 (Sigma-Aldrich), after which Alexa Fluor-labeled
secondary antisera (Life Technologies) were applied in the same solution for 1 hr at
room temperature. Nuclei were stained with 3 mM DAPI.

Immunofluorescence assays for cardiomyocytes
Cells were fixed in 4 % formaldehyde for 10 min with shaking at room temperature,
permeabilized for 5 min with 0.5 % Triton X-100 in PBS, and blocked for 1 hr at room
temperature with 5 % BSA in PBS containing 0.1% Triton X-100. The cells were labeled
overnight at 4 ˚C with the primary antibodies anti-Ki67 (1:200, 275R, Cell Marque) and
anti-phosphorylated histone 3 (1:200, 9701, Cell Signaling) for. After three washes with
PBS, samples were labeled for 1 hr at room temperature with fluorescent secondary
antibodies (Abcam) followed by 10 min of DAPI staining for nuclear visualization. After
three washes in PBS, cells were imaged with a Nikon Eclipse Ti2 microscope.

Immunofluorescence imaging of retinal organoids
Fresh frozen sections were permeabilized and blocked in a humidified chamber for 1 hr
at room temperature with 3 % horse serum in PBS with 0.3 % Triton X-100. The slides
were exposed for 2 hr to primary antibodies diluted in the same solution. Anti-Sox-9
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(1:100, Rb Cell Signaling 82630) was used to mark Müller cells. Slides were washed
three times with PBS. Secondary antisera (Alexa-Fluor 488 and 647) diluted 1:10,000 in
the serum solution were added for 1 hr at room temperature followed by two washes
with PBS. Labeling for 30 min at room temperature (Apply Click-iT Invitrogen Alexa
Fluor 555 C10338) was followed by a wash with PBS. After incubation with DAPI
(1:10,000 in PBS) for 5 min and the application of mounting solution, sections were
imaged by confocal microscopy with a Zeiss LSM 700 system with a 20X/0.8 NA
objective lens with a pinhole size set at the first Airy disc.

Protein immunoblotting and quantification
MCF 10A, HEK293 cells, retinal organoids, and utricles were lysed on ice in
radioimmunoprecipitation assay buffer solution (RIPA; BP-115-5x) with protease
inhibitors (Halt Protease Inhibitor Cocktail, Thermo 87786). Utricles were additionally
sonicated thrice at low power for 10 s, with breaks of 20 s with the samples kept on ice
between sonications After lysates had been scraped and centrifuged at 10,000 RPM for
10 min at 4 ˚C, the supernatants were immediately subjected to electrophoresis or
stored at -80 ˚C.
A standard immunoblotting protocol was used with the following specifications. A
4-12 % bis-tris gel (Thermo NP0322) was used to resolve the proteins in 5 mg of each
sample. The proteins were transferred to a nitrocellulose membrane (BioRad 1704156)
and blocked for 1 hr at room temperature (Rockland MB-070). After primary antibodies
had been reconstituted in the same solution, the membrane was incubated overnight at
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4 ˚C. After three 5 min washes at room temperature in tris-buffered saline solution with
0.05 % Tween 20, a secondary antibody conjugated to horseradish peroxidase
(Millipore) was applied in the same solution for 1 hr at room temperature before activity
was detected (SuperSignal West Pico PLUS, Thermo 34580). Images were acquired
with an iBrightFL1000 system.
We used at a dilution of 1:1000 primary antibodies directed against Yap
(sc-101199), phospho-Yap S127 (CST 4911), Lats1 and Lats2 (Abcam, ab70565),
phospho-Lats1 S909 (CST 9157), Mst1 (CST 3682), Mob1 (CST 13730),
phospho-Mob1 T35 (CST 8699), tubulin (Sigma T6793), and GAPDH(Abcam ab8245).
Cultured cardiomyocytes were lysed using RIPA supplemented with protease
and phosphatase inhibitors (1:100, Sigma). Lysates were prepared and 30 µg protein of
each sample was fractionated by gel electrophoresis in tris-glycine acrylamide gels, and
subsequently transferred to a PVDF membrane. Following 1 hr blocking at room
temperature, membranes were incubated with the following antibodies against
phospho-Yap at s112 (1:1000, 13008, cell signaling), Yap (1:2000, NB110-58358,
Novus) and Rabbit anti GAPDH (1:8000, PLA0125, Sigma) for 1 hr at room
temperature. Following two washes in tris-buffered saline solution containing 0.1 %
Tween 20, membranes were incubated with horseradish peroxidase anti-rabbit or
secondary antibodies (Jackson). The signal was detected by super-signal west pico
plus chemiluminescence kit (34580, Thermo-Fisher).
Immunoblots were quantified through measurement of band intensity with Fiji30.
The final value of each band’s intensity was normalized by the sum of all the bands’
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intensities. Significances from one-sided Student’s t-tests are denoted as follows: *,
p < 0.05; **, p < 0.01; ***, p < 0.001; ****, p < 0.0001.

Imaging of Yap nuclearization and quantification of proliferation
Confocal imaging was conducted with a confocal microscope enhanced with structured
illumination (VT-iSIM, VisiTech International Ltd.).
For quantification of Yap nuclearization, for each condition two fields of
supporting cells were imaged at 60X from two utricles. Using CellProlifer31, we masked
Sall2-positive nuclei and measured the intensity of their labeling. The same mask was
then applied to the Yap channel and the intensity of labeling was measured. The ratio of
the Yap to the Sall2 intensity was calculated for each condition in 680 cells after TRULI
treatment and 570 cells for DMSO controls.
For quantifying the proliferation of supporting cells, we imaged utricles at 60X,
then assembled the images into a composite tiling (Grid Collection Stitching, Fiji). The
maximal values in z-stacks were projected to display the entire supporting-cell layer of
the sensory epithelium, excluding connective tissue and the surrounding epithelium.
Using CellProlifer31, we counted the number of EdU-positive nuclei. Alternatively, EdUand Sox2- doubly positive nuclei were counted using Multi-point Tool in ImageJ.
Images acquired from neonatal cardiac cultures were analyzed using ImageJ
software by thresholding for cardiomyocytes according to endogenous tdTomato
fluorescence. Thresholded figures were carefully and manually separated by fine lines
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to de-cluster cells in case they touch, basing on original images, following by
measurements of area and solidity.
Images acquired from retina organoids were analyzed with CellProfiler31. Masks were
created for all the Sox9-positive nuclei, and the percentage of EdU- and Sox9-positive
nuclei were counted.

In vitro kinase assay
The in vitro kinase assay (HTRF KinEASE-STK S1, CisBio 62ST1PEB) was optimized
to the linear reaction range of the enzymes Lats1 (Carna 01-123) and Lats2
(Carna 01-124). Reactions were conducted with 10 µM STK1 substrate and 10 µM ATP,
unless otherwise indicated. For the ATP-shift assay, ATP was also used at
concentrations of 50 µM and 250 µM. Lats1 was employed at a concentration of 200
pg/µL and Lats2 at 50 pg/µL, unless otherwise indicated. For the assay in which
Michaelis-Menten constants for ATP were determined, each enzyme was at a
concentration of 62.5 pg/uL, and Lats1 ran for 30 min, and the Lats2 ran for 20 min, all
at room temperature. The DMSO concentration was maintained at 0.5 % (vol/vol)
throughout all experiments, and a Janus 384 MDT (PerkinElmer) equipped with a 50 nL
Pintool (V&P Scientific, Inc.) was used to add the compounds dissolved in DMSO to the
reaction. The enzyme, substrate, ATP, and TRULI were combined in a low-volume 384well plate and shaken for 50 min at room temperature, unless otherwise indicated. The
reaction was stopped by adding the detection reagents, which were prepared at an 8:1
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biotin:streptavidin ratio, and shaken for 60 min at room temperature. All reactions were
conducted in triplicate and a Synergy NEO (Biotek) was used to detect the signal.

Cellular kinase assay
HEK293A cells were plated overnight in 96-well culture plates at a density of 50,000
cells per well in the medium described above. To start the assay, new serum-free
medium with various concentrations of the compound was added to the cells, which
were then incubated for 30 min at 37 ˚C. The DMSO concentration was kept at 0.1 %
(vol/vol), and all experiments were performed in triplicate.
Total Yap and phospho-Yap were detected according to the two-plate protocol
for adherent cells (Total Yap Cellular Kit, Cisbio 64YATPEG; phospho-Yap [Ser127]
Cellular Kit, Cisbio 64YapPEG). The signal was detected by Synergy NEO (Biotek).
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Chapter 3
Explant Studies on Screen Hits

Having found the six validated hits in the primary screen, we turned to our model
system of interest, adult murine utricle explants, to test our original hypothesis that Yap
activation could drive supporting cell proliferation. I assayed the hits at various
concentrations and times, using immunohistochemistry to assess Yap activation and
ensuing proliferation. During our screen XMU-MP-1, an inhibitor of the Mst1/2 kinases,
was published, so we included it in our analysis as well32. Ultimately, of the seven
compounds tested, only one, RU-5757, demonstrated all the characteristics of interest.

Section 3.1: Adult Murine Utricle Explants
RU-5757, or N-(3-benzylthiazol-2(3H)-ylidene)-1H-pyrrolo[2,3-b]pyridine-3-carboxamide,
drove robust Yap nuclear translocation after 24 hr of treatment at a concentration of
10 µM (Fig. 3.1) and caused a striking reduction in the level of Yap phosphorylation. After
5 d of treatment, this substance evoked robust re-entry into the cell cycle of adult utricular
supporting cells (Fig. 3.2). For the sake of brevity we term this substance "TRULI."
Although XMU-MP-1 modestly reduced the amount of phospho-Yap, it decreased
the total Yap by a greater amount so that the ratio of phospho-Yap:total Yap actually
increased (Fig. 3.3). No significant proliferation was observed after 5 d of treatment
(Fig. 3.4).
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Figure 3.1| TRULI drives Yap nuclearization. (A) Immunohistochemistry demonstrates
that TRULI exposure drives Yap, yellow, into the nuclei of utricular supporting cells.
Sall2, green, is a nuclear marker of supporting cells (B) The nuclear localization of Yap
is quantified as a ratio to the constitutively expressed protein Sall2 (p < 0.0001 by an
unpaired, two-tailed t-test, n = 570 control nuclei and 680 treated nuclei).
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Figure 3.2| TRULI drives supporting cell proliferation. (A) In vitro exposure to TRULI
for 5 d elicits proliferation of supporting cells, as measured by the incorporation of EdU.
Verteporfin, an inhibitor of the Yap-Tead interaction, drastically reduces this effect.
(B) The number of EdU-positive cells per utricle increases with TRULI (p = 0.021 by an
unpaired, one-tailed t-test, control n = 2, TRULI n = 3), but the effect is blocked by
verteporfin (p = 0.028 by an unpaired, one-tailed t-test, n = 2).
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Figure 3.3| XMU-MP-1 fails to activate Yap. (A) Six utricles per condition were treated
for 24 hr with 10 µM TRULI or XMU-MP-1 to assess effects on the amount of
phospho-Yap by comparison to control conditions. (B) Quantification of band-intensity
ratios for phospho-Yap and total Yap in the immunoblot of panel A shows that
XMU-MP-1 does not reduce the fraction of phosphorylated Yap.
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Figure 3.4| XMU-MP-1 fails to drive supporting cell proliferation. When adult mouse
utricles were explanted and cultured with EdU (white) and either TRULI or varying
concentrations of XMU-MP-1 for 5 DIV, the latter caused no increase in proliferation.
Nuclei are stained with DAPI (blue).
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Section 3.2: Yap Dependence of TRULI-Mediated Proliferation
To test whether the proliferative effect of TRULI is exerted through Yap, we cotreated explants with TRULI and 5 µM verteporfin, an inhibitor of the interaction between
Yap or Taz and Tead transcription factors33. Consistent with the hypothesis, co-treatment
with verteporfin precluded a proliferative response (Fig. 3.2) To confirm these results, a
collaborator at USC, Ksenia Gnedeva, used SOX2-CreER and Yapfl/fl mice to generate
inducible conditional-knockout animals deficient for the protein in the sensory organs of
the inner ear34,35. Owing to the extensive lifetime of Yap protein36, Cre-mediated
recombination was induced either 7 d or 14 d prior to utricular explantation and culture.
In the utricles isolated from Yapfl/fl littermate mice lacking Cre recombinase, treatment
with TRULI elicited robust proliferation of supporting cells25. In contrast, in utricles
explanted from Yap knockout animals, proliferation was significantly reduced.
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Chapter 4
Elucidation of TRULI’s Mechanism

Having demonstrated that TRULI drives Yap-mediated supporting cell proliferation in
the adult murine utricle, we aimed to determine its mechanism of action. To this end,
we employed two cell line models with distinct methods of activating Hippo signaling.
Within these contexts we applied TRULI and found that in both, it interferes with the
ability of Lats1/2 to phosphorylate Yap, either directly or indirectly. The structure of
TRULI contains a hinge-binding motif indicative of ATP-pocket-binding mechanism of
inhibition. To test this hypothesis, we developed an in vitro kinase assay (IVKA) to
characterize the inhibitory potency of TRULI on Lats1/2. Together, these experiments
demonstrate that TRULI is an ATP-competitive inhibitor of the Lats1/2 kinases.

Section 4.1: Initial Assessment of TRULI Mechanism
After treatment of confluent MCF10a cells with 10 μM of TRULI for 24 hr, protein blotting
revealed that the Hippo signaling cascade was intact through the phosphorylation of the
activation loops of Lats1 (S909) and Lats2 (S872) (Fig. 4.1). However, the
phosphorylation of Yap at residue S127 was decreased, suggesting that TRULI is—
directly or indirectly—an inhibitor of Lats kinases.
To confirm this inference we turned to HEK293A cells, which activate Lats kinases
in response to serum starvation and thus inactivate Yap to prevent growth during nutrient
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Figure 4.1| TRULI prevents Lats-mediated Yap phosphorylation in confluent
MCF10a cells. Protein immunoblotting discloses that 24hr treatment of MCF 10A cells
with TRULI leaves Hippo signaling intact through the activation of Lats kinases, but that
Yap phosphorylation is greatly diminished.
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deprivation37,38. We pre-treated 80 % confluent HEK293A cells with 10 μM TRULI for 1 hr,
followed by 30 min of serum starvation. In control cultures, starvation elicited robust
phosphorylation of Lats1 at S909 and the consequent phosphorylation of Yap at S127
(Fig. 4.2). In cultures pre-treated with TRULI, however, serum starvation failed to evoke
phosphorylation of Yap despite the activation of Lats1. Even under treated, serum-fed
conditions, phospho-Yap levels were below those of serum-fed control cells. Negativefeedback regulation in response to elevated Yap activity might explain why the amount of
Lats1 S909 was enhanced in the treated, serum-fed condition39. These results together
confirmed that TRULI interferes with the ability of Lats kinases to phosphorylate Yap.

Section 4.2: ATP-competitive, Direct Inhibition of Lats1/2
The structure of TRULI includes a 7-azaindole moiety characteristic of the hinge-binding
motifs of ATP-competitive kinase inhibitors (Fig. 4.3A) Because there are no available
crystal structures of the Lats kinases, collaborators at the Tri-Institutional Therapeutics
Discovery Institute created a homology model from the crystal structure of the ATP pocket
of similar kinase ROCK1 bound to a small-molecule inhibitor containing a 7-azaindole
moiety. A putative structure of the complex between Lats1 and TRULI was then generated
by molecular docking25. Because the predicted protein-ligand contact residues of Lats1
and Lats2 are almost completely conserved, the model suggests that TRULI can bind
either with similar inhibitory potencies.
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Figure 4.2| TRULI prevents Lats-mediated Yap phosphorylation in serum-starved
HEK293A cells. Serum starvation of HEK293A cells in the presence of TRULI also
demonstrates Lats activation but suppression of Yap phosphorylation.
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Figure 4.3| TRULI is an ATP-competitive inhibitor of the Lats kinases. (A) TRULI
comprises a thiazolimine backbone with two substituents: a benzyl group and a
7-azaindole hinge-binding motif. (B) An in vitro assay of Lats1 kinase activity shows that
the IC50 for TRULI increases with the ATP concentration, from 0.2 nM at 10 µM, to 4.3 nM
at 50 µM, and to 80 nM at 250 µM, demonstrating that the compound is an ATPcompetitive inhibitor. (C) The half-maximal inhibitory concentration of TRULI against
Lats2 was IC50 = 0.2 nM.
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To test our speculations about the mechanism of TRULI inhibition, we optimized
an in vitro kinase assay with truncated forms of Lats1 (residues 589-1130) and Lats2
(residues 553-1088) that include primarily the kinase domains. As a substrate we
employed the peptide STK1, which is known to be phosphorylated by these enzymes40.
Because we hypothesized TRULI was ATP-competitive, we first determined the
Michaelis-Menten constants of Lats1 and Lats2 for ATP to be near 10 µM for both
enzymes25; we then conducted the initial in vitro kinase assays at that concentration.
Under these conditions, we found that TRULI directly inhibits both Lats1 and Lats2 with
a half-maximal inhibitory concentration (IC50) of 0.2 nM (Fig. 4.3B,C). In view of these
results, we named the compound TRULI: “The Rockefeller University Lats inhibitor." In
support of our hypothesis, increases in ATP concentrations yielded positive shifts in the
IC50 (Fig. 4.3B).
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Chapter 5
The Effects of TRULI in Other Contexts

Because the regenerative effects of activating Yap in organs such as the retina and heart
have been characterized extensively18,19,41,42, we investigated whether TRULI treatment
is effective in eliciting cellular proliferation in these organs. The results demonstrate that
TRULI can faithfully reproduce prior results, otherwise derived with cumbersome
techniques, and thus TRULI is likely to be a widely applicable approach for researchers
in various fields. Moreover, derivatives of TRULI, which are optimized for in vivo
application, may offer therapeutic modalities in various pathologies.

Section 5.1: Cardiomyocyte Data
The proliferative capacity of cardiomyocytes in culture and the capacity of the heart
to regenerate decline sharply after birth41. To ascertain whether TRULI activates Yap and
induces regeneration, collaborators at Weizmann Institute exposed P0 murine
cardiomyocytes to TRULI for 3 d. In control cultures, protein blotting revealed high levels
of phospho-Yap indicative of Hippo activity. TRULI treatment reduced the proportion of
phosphorylated Yap and induced cardiomyocyte proliferation, as demonstrated by a
significant increase in the percentage of cells positive for the markers Ki67 ad
phosphorylated histone H3 (Fig. 5.1A-E). Moreover, treated cells developed cytoskeletal
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rearrangements and protrusions and decreased in size, phenotypes consistent with
de-differentiation (Fig. 5.1F,G)43.

Section 5.2: Retina Organoid Data
Yap activation can induce retinal regeneration by increasing the proliferation of
Müller glial cells, progenitors with a capacity to differentiate into photoreceptors and
neurons19,20. To test whether TRULI induces the proliferation of Müller glia, collaborators
at Children’s Hospital of L.A. used retinal organoids derived from human induced
pluripotent stem cells. Western blotting demonstrated loss of Yap phosphorylation in 24
hr TRULI-treated organoids. And while Müller cells remained largely quiescent in control
cultures, in organoids treated for 5 d with 10 µM TRULI, Müller cells exhibited a robust
increase in proliferation (Fig. 5.2).
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Figure 5.1| TRULI activates Yap in neonatal murine cardiomyocytes, driving
proliferation. (A) A protein immunoblot indicates that TRULI decreases the
phosphorylation of Yap in neonatal cardiomyocytes in vitro. (B) Quantification of the data
in panel A shows the significance of the effect (p = 0.008 by an unpaired, two-tailed t-test,
n = 4). (C) Immunofluorescent labeling discloses that 3 d of TRULI treatment elevates the
cell-cycle marker Ki67 (arrowheads) in cardiomyocytes. Scale bars, 50 µm.
(D) Quantification again reveals significant effects for Ki67 (p = 0.001 by an unpaired,
two-tailed t-test, n = 4). (E) A marker of mitotic initiation, pH3, is similarly elevated by
treatment (p = 0.026 by an unpaired, two-tailed t-test, n = 4). (F) The cardiomyocyte
solidity, an index of cellular shape, decreases significantly after treatment, an effect
consistent with de-differentiation (p < 0.0001 by an unpaired, two-tailed t-test, n = 232
control cells and 197 TRULI-treated cells). (G) TRULI treatment reduces the areas of
cardiomyocytes, another sign of mitosis (p < 0.0001 by an unpaired, two-tailed t-test,
n = 231 control cells and 197 TRULI-treated cells).
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TRULI

Figure 5.2| TRULI activates Yap in human retinal organoids, driving proliferation.
(A) A protein immunoblot indicates that 24 hr of treatment with TRULI decreases the
phosphorylation of Yap in Sox9-marked Müller cells of human retinal organoids. (B) A bar
graph documents the effect observed in panel A (p = 0.024 by an unpaired, two-tailed
t-test, n = 3). (C) After 5 d of TRULI treatment, EdU labeling shows a substantial increase
in cellular proliferation. (D) A bar graph quantifies the result of panel C in three
experiments (p < 0.0001 by an unpaired, two-tailed t-test, n = 15 control organoids and
16 TRULI-treated organoids).
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Chapter 6
Further Characterization of TRULI and its Derivatives

In collaboration with the Tri-Institutional Therapeutics Discovery Institute (TDI) we were
able to characterize various aspects of TRULI, and the techniques we employed
originally became the pipeline with which to screen derivatives generated through
medicinal chemistry. In addition to the in vitro kinase assay we used in our laboratory,
we developed an in-cell assay for determining the half-maximal effective concentration
of TRULI on Lats-mediated Yap phosphorylation in live cells. When combined with data
generated by TDI, both in house and through contract research organizations, these
techniques demonstrated that TRULI is a direct, potent, and relatively selective inhibitor
of Lats1/2 kinases. After several generations of optimization, lead compounds
demonstrated 1000-fold increases in in vitro potency and more than 10-fold increase in
in-cell potency and mouse utricle explant sensitivity. The most potent derivatives also
halved the time required for the effect in utricle explants, a promising development for in
vivo applications. The final suite of derivates varies across systemic stability, potency,
selectivity, and more, yielding a diverse arsenal of compounds that may contain
components matching the needs of future biological investigations. Because these
compounds are protected under a provisional patent, and much of the intellectual work
of designing derivatives was done by TDI, the process of compound optimization is
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described in abstract terms, with a focus on elements performed or analyzed in our
laboratory.

Section 6.1: In-Cell Potency
To determine the in-cell potency of TRULI, we evaluated the content of total Yap
and phospho-Yap in HEK293A cells serum-starved in the presence of various
concentrations and determined the half-maximal effective concentration of the compound
to be 510 nM (Fig. 6.1).

Section 6.2: Data from Tri-Institutional Therapeutics Discovery
Institute
To assess the selectivity of TRULI, collaborators at TDI first compared the
sequences of the putative ATP-binding residues of Lats1 and Lats2 with those of other
members of the AGC kinase family25,44. To determine which of these potential off-target
kinases are bound, we tested TRULI in a broad kinome-binding panel45. Of the 314
kinases tested, 34 bound TRULI more strongly than did Lats1 (Table 6.1A). These values
likely represent an upper bound on the number of enzymes susceptible to cross-reactivity:
although only kinases bound by a small molecule might be relevant, not all such enzymes
are functionally inhibited. The selectivity score, or percentage of kinases for which the
inhibitor has an half-maximal displacement concentration below 1 µM, was 18.1. This
value compares with 86.0 for the broad-spectrum kinase inhibitor staurosporine and with
18.8 for the clinically approved, selective tyrosine kinase inhibitor dasatinib. To assess
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Figure 6.1| In-cell determination of TRULI potency. A kinase assay conducted with
serum-starved HEK293A cells indicates a half-maximal effective concentration of 510 nM
for TRULI. Starvation does not significantly deplete the total amount of Yap.
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Table 6.1| Specificity of TRULI in binding and function. Colors identify different subfamilies of the AGC kinase family. (A) Of 314 kinases in a binding panel, the indicated
enzymes bound 1 µM TRULI more strongly than did Lats1 or Lats2. The assay did not
test for functional inhibition. (B) Half-maximal inhibitory concentrations (IC50s) of TRULI
for selected kinases.
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whether some of the kinases identified in both approaches were in fact functionally
inhibited, we measured half-maximal inhibitory concentration values against four kinases
that were high on both lists and represented by multiple family members (Table 6.1B)46.
Confirming our assumption, the range of inhibitory potency spanned from 14 nM, a
relatively strong inhibition, to 1000 nM, effectively no inhibition. Although it will be
necessary to explore other potential off-target kinases, particularly in a tissue-specific
context, these data demonstrate that TRULI is a potent, direct, and relatively selective
inhibitor of Lats1 and Lats2.
To explore the broader characteristics of TRULI, TDI also performed standard
metabolic and toxicology analysis, establishing starting points for the next stage of
compound optimization.

Section 6.3: Medicinal Chemistry
Drawing on an extensive background of expertise, medicinal chemists from TDI
used the limited information at hand to optimize compounds. After dozens of compounds
had been designed and synthesized, our group performed the in vitro kinase assay,
always with controls of TRULI, to look for improved potencies. Superior compounds were
noted, and TDI gleaned the lessons from the data, informing new generations of
derivatives. Particularly good compounds from each generation were repeated in the in
vitro kinase assay and then assessed in the in-cell assay.
TRULI was optimized across its three moieties (Fig. 6.2): hinge-binding, core, and
hydrophobic R-group. Not surprisingly, most modifications to the hinge-binding region
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Figure 6.2| Medicinal chemistry approaches. TRULI comprises three regions: a
thiazolimine backbone (green), a hydrophobic benzyl group (blue), and a 7-azaindole
hinge-binding motif (red).
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yielded complete loss of inhibition. Although many modifications within the core and
hydrophobic regions were also found to decrease potency, numerous alterations were
found that dramatically increased the compounds’ potencies.
In addition to our assessment of derivative potency, TDI performed
pharmacokinetic, toxicity, and specificity studies on the best derivatives of each
generation to assess for improvements along these other key characteristics.

Section 6.4: Lead Compounds
After 60 compounds had been made over a period of six months, the best were
1000-fold more potent than TRULI in the in vitro kinase assay and up to 50-fold more
potent in mouse utricle explants (Fig. 6.3). Of particular interest for in vivo pursuits, the
best compounds were not only more potent, but also halved time required for an effect
in adult mouse utricle explants, at a 10-fold lower dosage than TRULI is used (Fig 6.4).
The contract research organization-based analyses also rounded out the
characterization of this suite, wherein some compounds demonstrate better specificity,
some better solubility, some high and some low systemic stabilities (Table. 6.2).
Altogether, this suite offers a robust arsenal of tools for a variety of needs of future
biological studies into Hippo-Yap, both in vitro and in vivo.
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Figure 6.3| Increased potency of derivatives. Concentrations as low as 100 nM of some
derivatives sufficed to drive supporting cell proliferation in adult murine utricle explants.
Supporting cell nuclear marker Sall2 (green); nuclei of proliferated cells labeled with Edu
(white).
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Figure 6.4| Decreased response latency in derivatives. In vitro treatment of adult
utricle explants with 1 µM of one derivative for only three days elicited robust proliferation;
by comparison, TRULI requires five days at 10 µM for a comparable response. Two
representative images are shown. Nuclei are labeled with DAPI (blue), and nuclei of
proliferated cells labeled with Edu (white).
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Table 6.2| Derivatives of TRULI. Two derivatives are shown compared to TRULI and its
qualities, as characterized by both in-house assays and information generated by TDI
through contract research organizations. Green indicates optimal ranges, yellow
intermediate values, and red poor quality. Half-maximal inhibitory concentrations (IC50),
as measured in the in vitro kinase assay, are noted in nanomolar. Over 60 derivatives
were generated and patented.
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Chapter 7
Discussion

Most experiments demonstrating the regenerative effects of Yap activation in
mammalian tissues have used transgenesis, viral transfection, or indirect approaches
such as activation of G protein-coupled receptors. Although these studies have provided
important proof-of-principle results, manipulation of Yap signaling with small molecules
offers a more feasible translational approach and simplifies further investigations. In the
work described thus far, our group identified and characterized TRULI, a small-molecule
inhibitor of the LATS1/2 enzymes. The results supported our original hypothesis that
Yap activation in adult murine utricle would drive supporting cell proliferation. Moreover,
TRULI reproduces findings from cardiomyocyte and retinal tissues, suggesting the
compound and its derivatives are broadly applicable to any investigator interested in
exploring Lats inhibition or Yap activation. Although in vivo studies with TRULI suggest
that its pharmacokinetic properties are insufficient for this application, the dozens of
superior derivatives generated significantly increase the likelihood of success in this
endeavor. TRULI and its derivates offer powerful tools for molecular investigations of
development, stem cell biology, regeneration, and more; it is even plausible that drugs
related to this novel thiazolimine class will prove useful in some therapeutic contexts.
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Section 7.1: Next Steps in the Inner Ear
TRULI offers a novel avenue into investigating the possibility of mitotic regeneration in
the mammalian inner ear. The next steps to achieve this goal include further
characterizing and optimizing the transdifferentiation of supporting cells into mature hair
cells, exploring the potential for Yap reactivation in the cochlea, and finally
demonstrating any and all of these steps in vivo.
The initial data on hair cell generation are promising. RNA-sequencing analysis
done by Dr. Ksenia Gnedeva showed that TRULI treatment reprograms supporting cells
in the utricle to a more plastic state25. After undergoing division, supporting cells re-enter
G0 upon drug withdrawal, and many cells shift their nuclei into the hair-cell layer; the
pattern is strikingly similar to the regenerative response in non-mammalian vertebrates6.
Although without a second perturbation in vitro, we did not observe markers for mature
hair cells by immunohistochemistry, daughter cells upregulate hair cell genes to a modest
extent.

Notch

inhibition

with

gamma-secretases

failed

to

improve

the

immunohistochemical readout. However, upon Atoh1 transduction, these cells
upregulated Pou4F3, an early hair cell marker. Further characterization of the possible
new hair cells is needed, including assessing electrophysiological activity, channel
patency, hair bundle formation, and other markers of maturity. The experiments
conducted heretofore involved explant culture, a fairly toxic environment for hair cells,
and therefore the system might simply have been incompatible with the generation of fully
mature hair cells. Taken together, our data suggest that combining Hippo inhibition with
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a second perturbation driving transdifferentiation might constitute an effective approach
to restoring hair cells.
One primary reason for using the utricle as a model organ is that the adult cochlea
is difficult to culture in explants and in vivo approaches are technically challenging.
Because a neonatal cochlea explant survives for days in culture, we were able to assess
the effect of TRULI in this context. After five days of exposure, supporting cells largely
remained quiescent, but there were strong proliferative effects in the greater epithelial
ridge, a transient developmental tissue thought to harbor precursor cells for the sensory
epithelia. Several issues might be at play. One key factor in several regenerative fields is
that proliferative responses are minimal without damage. In the adult utricle explant, it is
known that over half of the hair cells die in culture within 24 hours, which might enable
the proliferation we observe. The hair cells of the neonatal cochlea remain intact,
however, which might preclude supporting cell proliferation. Moreover, the epigenetic
status of cochlear cells has been shown to be more restrictive, and the chromatin less
accessible, than is the case for the utricle47. These factors suggest that either damage,
more potent derivatives, or longer exposure might tip the scales towards regeneration. If
these approaches fail to drive supporting cell proliferation, multiple pathways might need
to be targeted. As described in the Introduction, several cyclin kinase inhibitors are active
in the cochlea, but not in the utricle, offering other potential targets.
Many of the aforementioned issues stem from the robust, but problematic, explant
system. We must ultimately prove the utility of Yap activation in vivo. Although technically
more challenging, this approach circumvents many of the issues at hand. The tissue is in
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its endogenous context, replete with its natural nutrients, growth factors, and blood
supply, in the correct ionic milieu, and more. With techniques that have been developed
to induce hair cell loss specifically, and without effecting the other cell types, we can
ablate these cells, followed by treatment with TRULI or its superior derivatives. Given the
pharmacokinetics of the compounds, the use of slow-release gels injected into the middle
ear will likely be a key aspect of our future approach. These experiments will enable us
to answer the remaining questions: can daughter cells in the utricle convert into mature,
functioning hair cells in the endogenous context, or is a second perturbation required; and
can Yap activation drive supporting cell in the mature organ of Corti?

Section 7.2: Other organs
Because TRULI can drive the proliferation of murine cardiomyoctyes and human Müller
cells, we believe that the compound could be widely applicable to various lines of
investigation into Hippo-Yap signaling. This pathways has been implicated in the
development of many tissue types; regeneration in the liver, intestine, lungs, and skin;
cancer45; numerous neurodegenerative diseases48; regulation of the mitotic spindle49;
cross-talk with important pathways such as Wnt50, p5351, Notch52, and estrogen
receptor51; and more. To further demonstrate the breadth of utility, we have initiated
several collaborations that have in part validated our expectations.
A potential concern about Lats inhibition is oncogenic transformation. The side
effects of Lats inhibition might be mitigated by local application in isolated fluid
compartments such as the endolymph of the inner ear, vitreous humor of the retina, and
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pericardium of the heart. Moreover, the relationship of Yap to cancer is complex. Yap
activation is a marker for poor prognosis in some cancers, but the opposite is true in other
instances49. Mutations of proteins in the Hippo pathway are rarely causative of cancer,
but are instead secondary to the molecular changes associated with tumorigenesis15. In
fact, activation of Yap through deletion of Lats kinases in certain syngenic tumors
decreases their progression and metastasis in immune-competent mice by augmenting
the immune response44. Given these results, we have established a collaboration with Dr.
Elaine Fuchs at Rockefeller University. Together, we will explore whether Yap activation
can mimic the effect of Lats deletion in these contexts. We hypothesize that treatment of
squamous cell carcinomas with TRULI in mice will slow tumor progression and decrease
metastasis.
Among the neurodegenerative disease, the role of Hippo-Yap signaling is the
best characterized in the pathophysiology of Huntington’s Disease54,55. One study
demonstrated that Yap activation in the nervous system of a mouse model of the
disease ameliorates behavioral deficits in vivo54. To test whether TRULI sheds light on
the mechanism of Huntington’s Disease, or offer insights into potential therapies, we are
collaborating with a team from Dr. Ali Brivanlou’s group at Rockefeller University. Using
human induced pluripotent stem cell (iPSCs)-derived neuruloids with mutations in the
huntingtin protein, we hope to explore the developmental relevance of deregulated Yap
signaling in Huntington’s Disease.
Yap activation has also been shown to augment the process of converting
fibroblasts to iPSCs56,57. To explore whether TRULI offers either an investigatory tool or
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a tool for improved iPSC generation, we have established a collaboration with Dr. Todd
Evans at Weill Cornell Medical College. Together we are assessing whether TRULI can
improve the generation of mouse and human iPSC’s, and furthermore we are exploring
what aspects of molecular biology within these systems this compound might illuminate.
Within our own group, we have also applied TRULI to the study of regenerating
neuromasts in the zebrafish. It is poorly understood how the number of sensory hair
cells is so tightly controlled, and the molecular signals underlying the regeneration these
cells are only partially understood. We are using TRULI to explore whether Hippo/Yap
signaling plays a role in this context; our preliminary results strongly suggest this
pathway is highly relevant to the process.
We are also continuing our collaboration with Drs. Aaron Nagiel and Ksenia
Gnedeva, who are attempting to extend our findings in retinal organoids to the retina in
vivo. We hope that the use of TRULI’s derivatives offers an approach to retinal
regeneration as well.
Together, these endeavors demonstrate that TRULI is a widely applicable and
useful tool in numerous potential areas of investigation.
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Summary
Hippo signaling is an evolutionarily conserved pathway that restricts organ growth during
development and suppresses regeneration in mature organs1–3. Using a high-throughput
phenotypic screen, we have identified a potent, non-toxic, and reversible inhibitor of Hippo
signaling. An ATP-competitive inhibitor of Lats kinases, the compound causes Yapdependent proliferation of murine supporting cells in the inner ear, murine
cardiomyocytes, and human Müller glia in retinal organoids. RNA sequencing indicates
that the substance fosters both the G1-S and G2-M checkpoint transitions and yields
supporting cells capable of transdifferentiation. Upon withdrawal of the compound, a
subset of supporting cells move their nuclei into the hair-cell layer and express genes
characteristic of hair cells. Viral transfection of Atoh1 induces the expression of hair cellspecific proteins in progeny. The compound promotes the initial stages of the proliferative
regeneration of hair cells, a process thought to be permanently suppressed in the adult
mammalian inner ear.

Introduction
Initiated in response to injury, regeneration is a complex process that can restore the
structure and function of damaged tissue. Some adult mammalian tissues retain a
gradually declining regenerative capability. Regeneration occurs either by activation and
amplification of resident stem cells, as in the epithelia of the skin and intestine, or through
cellular de-differentiation and proliferation, as in the liver. In other instances, such as
central nervous and cardiac-muscle tissues, cells exhibit little or no potential for
regeneration after injury1,4,5.
One prominent example of a mammalian organ with poor regenerative capacity is
the inner ear6,7. The auditory and vestibular sensory epithelia of all vertebrates possess
only two major cell types: supporting cells, which play homeostatic and architectural roles,
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and mechanosensitive hair cells. In non-mammalian vertebrates such as birds, lost hair
cells are replaced by residual supporting cells that transdifferentiate into new sensory
receptors either directly or after undergoing division8. Although modest numbers of hair
cells regenerate through supporting-cell transdifferentiation in the neonatal mammalian
cochlea9 and in neonatal and adult vestibular organs10, after the first postnatal week no
proliferative response occurs following damage11,12.
In view of its fundamental roles in development, proliferation, stem-cell
maintenance, and de-differentiation, Hippo signaling is an inviting target for driving
regeneration1,3. The canonical Hippo pathway is a highly conserved signal-transduction
cascade that comprises two pairs of core kinases. When proliferation is unwarranted,
Mst1 and Mst2 phosphorylate Lats1 and Lats2; these proteins in turn phosphorylate the
transcriptional co-activator Yap and its homolog Taz, which as a result are sequestered
and degraded in the cytoplasm. When the pathway is inactive, Yap enters the nucleus,
interacts with transcription factors of the Tead family, and initiates cell division2. Yap
signaling integrates a variety of information from the cellular environment, including
biomechanical cues, cell density, cell polarity, metabolic challenges, and signals such as
Notch and Wnt. The Hippo cascade is the conduit through which much, but not all, of this
information is integrated into a decision regarding Yap activation13.
The regenerative potential of the Hippo pathway has become abundantly clear in
numerous organs, including the heart5,14–16, retina17, liver, and intestine18. We earlier
demonstrated that Hippo signaling limits the size of the developing murine utricle, a
vestibular sensory organ, and that the Yap-Tead complex is active during—and
necessary for—proliferative regeneration in the neonatal utricle19. These observations
suggested that chemical activation of Yap signaling might engender supporting-cell
proliferation in adult tissue, a key missing step in the regeneration of the mammalian inner
ear. We therefore conducted a small-molecule screen for Yap activators.
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Results
Identification of activators of Yap signaling
In some monolayer epithelial cultures, increased cell density leads to Hippo activation
and thus retention and degradation of Yap protein, a process reminiscent of growth
restriction during normal development20,21,22. To seek inhibitors of this process, we
designed a high-throughput phenotypic screen for compounds that promote nuclear Yap
translocation in confluent human cell cultures (Fig. 1A). After testing three lines, we chose
MCF 10A mammary epithelial cells, which demonstrated a robust negative correlation
between cellular confluence and the fraction of cells with nuclear Yap (Figs. 1B,C and
S1A).
For the small-molecule screen, we seeded MCF 10A cells to achieve dense cultures
in 384-well plates. A single compound was deposited in each well at a concentration of
10 µM. Every plate also included a positive control, sub-confluent cells, and a negative
control, densely cultured cells, both exposed to dimethyl sulfoxide (DMSO) at a
concentration equivalent to that in which the compounds were applied. After 24 hr
incubation, we determined the fraction of the cells with nuclear Yap and compared that
value to the median negative-control value (Fig. 1D). We also scored the total number of
surviving cells in each well and eliminated the compounds that decreased the number by
more than one standard deviation in comparison to the dense control cultures. Nontoxic
compounds that increased nuclear Yap by more than one standard deviation in
comparison to the negative control were scored as hits (Fig. S1B,C). Owing to the
robustness of contact inhibition in the dense cell cultures, only six of the compounds
screened met these criteria.
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Yap-dependent proliferation of supporting cells evoked by TRULI
Using utricles isolated from mice eight to twelve weeks of age , we next tested the effects
of the the six compounds identified in the screen. Four elicited appreciable Yap nuclear
translocation, but only two evoked supporting-cell proliferation. Of the two proliferationinducing compounds, one required a concentration in excess of 100 µM and appeared
toxic

to

hair

cells.

The

final

compound,

N-(3-benzylthiazol-2(3H)-ylidene)-

1H-pyrrolo[2,3-b]pyridine-3-carboxamide, drove robust Yap nuclear translocation after
24 hr of treatment at a concentration of 10 µM and caused a striking reduction in the level
of Yap phosphorylation (Figs. 2A,B,D and S2A). After 5 d of treatment, this substance
evoked robust re-entry into the cell cycle of adult utricular supporting cells (Fig. 2C,E).
For the sake of brevity we term this substance "TRULI."
We also tested the recently published inhibitor of Mst1 and Mst2 kinases18,
XMU-MP-1. Although XMU-MP-1 reduced the amount of phospho-Yap, it decreased the
total Yap by a greater amount so that the ratio actually increased (Fig. S2A,B). No
significant proliferation was observed after 5 d of treatment (Fig. S2C).
We additionally assessed the effect of TRULI in the murine cochlea. Although a
proliferative response was observed in Kölliker's organ, where progenitor-like cells
capable of differentiating into both hair and supporting cells reside23,24, all but the most
lateral rows of supporting cells in the organ of Corti remained postmitotic after treatment
with TRULI (Fig. S3).
To test whether the proliferative effect of TRULI is exerted through Yap, we cotreated explants with TRULI and 5 µM verteporfin, an inhibitor of the interaction between
Yap or Taz and Tead transcription factors25. Consistent with the hypothesis, co-treatment
with verteporfin precluded a proliferative response (Fig. 2C,E). To confirm these results,
we used SOX2-CreER and Yapfl/fl mice to generate inducible conditional-knockout animals
deficient for the protein in the sensory organs of the inner ear26,27. Owing to the stability
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of Yap protein28, Cre-mediated recombination was induced either 7 d or 14 d prior to
utricular explantation and culture. In the utricles isolated from Yapfl/fl littermate mice
lacking Cre recombinase, treatment with TRULI elicited robust proliferation of supporting
cells (Fig. 2F,G). In contrast, in utricles explanted from Yap knockout animals,
proliferation was significantly reduced.
Blockage of Lats-dependent Yap phosphorylation by TRULI
We investigated the mechanism of TRULI’s inhibition in the MCF 10A cell line. After
treatment of confluent cells with 10 μM of TRULI for 24 hr, protein blotting revealed that
the Hippo signaling cascade was intact through the phosphorylation of the activation
loops of Lats1 (S909) and Lats2 (S872) (Fig. 3A). However, the phosphorylation of Yap
at residue S127 was decreased, suggesting that TRULI is—directly or indirectly—an
inhibitor of Lats kinases.
To confirm this inference we turned to HEK293A cells, which activate Lats kinases
in response to serum starvation and thus inactivate Yap to prevent growth during nutrient
deprivation29,30. We pre-treated 80 % confluent HEK293A cells with 10 μM TRULI for 1 hr,
followed by 30 min of serum starvation. In control cultures, starvation elicited robust
phosphorylation of Lats1 at S909 and the consequent phosphorylation of Yap at S127
(Fig. 3B). In cultures pre-treated with TRULI, however, serum starvation failed to evoke
phosphorylation of Yap despite the activation of Lats1. Even under treated, serum-fed
conditions, phospho-Yap levels were below those of serum-fed control cells. Negativefeedback regulation in response to elevated Yap activity might explain why the amount of
Lats1 S909 was enhanced in the treated, serum-fed condition31. These results together
confirmed that TRULI interferes with the ability of Lats kinases to phosphorylate Yap.
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Direct inhibition of Lats1 and Lats2 by TRULI
The structure of TRULI includes a 7-azaindole moiety characteristic of the hinge-binding
motifs of ATP-competitive kinase inhibitors (Fig. 3C) Because there are no known crystal
structures of the Lats kinases, we created a homology model from the crystal structure of
the ATP pocket of similar kinase ROCK1 bound to a small-molecule inhibitor containing
a 7-azaindole moiety. A putative structure of the complex between Lats1 and TRULI was
then generated by molecular docking (Fig. 3D). Because the predicted protein-ligand
contact residues of Lats1 and Lats2 are almost completely conserved, the model
suggests that TRULI can bind either with similar inhibitory potencies.
To test our speculations about the mechanism of TRULI inhibition, we optimized
an in vitro kinase assay using truncated forms of Lats1 (residues 589-1130) and Lats2
(residues 553-1088) that include primarily the kinase domains (Fig. S4A-C). As a
substrate we employed the peptide STK1, which is known to be phosphorylated by these
enzymes32. Because we hypothesized TRULI was ATP-competitive, we first determined
the Michaelis-Menten constants of Lats1 and Lats2 for ATP to be near 10 µM for both
enzymes, at which we ran the initial in vitro kinase assays (Fig. S4A). Under these
conditions, we found that TRULI directly inhibits both Lats1 and Lats2 with a half-maximal
inhibitory concentration (IC50) of 0.2 nM (Figs. 3E and S4D), whence the name TRULI:
“The Rockefeller University Lats inhibitor." In support of our hypothesis, increases in ATP
concentrations yielded positive shifts in the IC50 (Fig. 3E).
To determine the potency of TRULI in living cells, we evaluated the content of total
Yap and phospho-Yap in HEK293A cells serum-starved in the presence of various
concentrations of TRULI. The half-maximal effective concentration of the compound was
EC50 = 510 nM (Fig. 3F).
To assess the selectivity of TRULI, we first compared the sequences of the
putative ATP-binding residues of Lats1 and Lats2 with those of other members of the
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AGC kinase family (Tables S1 and S2)33. To determine which of these potential off-target
kinases are bound, we tested TRULI in a broad kinome-binding panel34. Of the 314
kinases tested, 34 bound TRULI more strongly than Lats1 (Table S3). These values
represent an upper bound: although only kinases bound by a small molecule might be
relevant, not all such enzymes are functionally inhibited. The selectivity score, or
percentage of kinases for which the inhibitor has a half-maximal concentration of binding
displacement below 1 µM, was 18.1. This value compares with control values of 86.0 for
the broad-spectrum kinase inhibitor staurosporine and of 18.8 for dasatinib, a clinically
approved selective inhibitor of tyrosine kinases. To assess whether some of the kinases
identified in both approaches were in fact functionally inhibited, we measured IC50 values
against four kinases that were high on both lists and represented by multiple family
members35. Some were affected significantly more strongly than others (Table S4).
Although it will be necessary to explore other potential off-target kinases, particularly in a
tissue-specific context, these data demonstrate that TRULI is a potent, direct, and
relatively selective inhibitor of Lats1 and Lats2.
Gene-expression consequences of TRULI treatment
To characterize the consequences of Lats-kinase inhibition with TRULI, we analyzed the
changes in gene expression triggered by the compound after 5 d of treatment. To facilitate
the sorting of supporting cells from treated utricles, we utilized Lfng-EGFP mice, whose
supporting cells bear a fluorescent tag36. Principal-component analysis of RNAsequencing data revealed that almost 60 % of the variance between TRULI-treated and
control samples could be explained by the first principal component and that the three
samples collected under each condition clustered closely along that axis (Fig. 4A). Over
70 % of differentially expressed genes whose expression changed by at least a factor of
two were upregulated after treatment (Fig. 4B). Gene ontology analysis37 demonstrated
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that the terms associated with regulation of the cell cycle were the most enriched amongst
up-regulated genes (Fig. 4C).
To assess the biological relevance of the changes in gene expression triggered by
TRULI, we compared the FPKM values for the differentially expressed genes to those
from late embryonic (E17.5) utricular supporting cells. At that stage such cells remain
highly plastic and are capable of both proliferation and differentiation into the new sensory
receptors38,39. The expression levels for most cell cycle-related genes (gene-ontology
term 0007049) that were differentially expressed in postnatal supporting cells after TRULI
treatment were highly similar to those in E17.5 supporting cells (Fig. 4D). In particular,
the genes specific to the G1-S and G2-M stages of the cell cycle were significantly upregulated by TRULI to the embryonic levels of expression (Fig. 4E,F). Consistent with the
pro-survival role of Yap-Tead signaling, TRULI repressed expression of a subset of
inflammatory and pro-apoptotic genes.
The direct targets of the Yap-Tead complex have been identified in other contexts,
such as in mammary cancer cells40. In accord with the compound's acting as an activator
of nuclear Yap signaling, over 90 % of confirmed direct downstream targets of Yap-Tead
complex identified within differentially expressed genes were up-regulated in response to
TRULI treatment (Fig. 4G,H). Consistent with our demonstration of a role for Yap in the
development of the utricular sensory epithelium41, most of these Yap-target genes were
also highly expressed in E17.5 supporting cells.
Inhibition of Lats kinases by TRULI had no apparent toxic effect on utricular
supporting cells: genes associated with cell death (gene-ontology term 0008219)
remained unchanged after treatment (Fig. 4I).
Supporting-cell differentiation after TRULI treatment
To determine whether the increased supporting-cell proliferation triggered by TRULI can
be reversed, we performed EdU pulse-chase experiments following TRULI treatment. The
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mitogenic effects of Lats inhibition persisted for 24-48 hr after drug withdrawal, for many
supporting cells incorporated EdU during that interval (Fig. S5). However, most
supporting cells exited the cell cycle thereafter.
Forcing postmitotic cells to re-enter the cell cycle can result in arrest at the G1-S
or G2-M checkpoint transition and consequently in programmed cell death42. To evaluate
the long-term outcome of Lats inhibition on supporting cells, we treated three-week-old
Lfng-GFP utricles with TRULI for 5 d followed by 5 d of withdrawal. RNA-sequencing
analysis demonstrated that the levels of expression for the cell cycle-related genes and
the direct Yap targets that were highly up-regulated upon TRULI treatment were
indistinguishable between TRULI-treated and control supporting cells (Fig. S6). In
addition, we did not observe enrichment for pro-apoptotic genes after TRULI treatment.
Instead, the up-regulated genes were associated with the gene-ontology terms related to
hair-cell development and function (Fig. 5A,B). These included the genes for hair cellspecific transcription factors such as Atoh1, Pou4f3, Gfi1, and Lhx3 as well as genes
encoding important hair-cell proteins: nonmuscle myosins (Myo15, Myo7A, Myo5A), Ca2+
sensors and buffers (Otof, Calb, S100), and transduction machinery (Tmc1, Tomt).
Because the foregoing results suggested the transdifferentiation of newly formed
supporting cells, we sought newly formed hair cells by EdU incorporation. Treatment with
TRULI did not affect hair-cell or supporting-cell survival, confirming that the compound is
not toxic at the effective concentration (Fig. 5C,D). Although almost none of the cells
expressed Pou4f3 or Myo7A, many of the EdU-positive supporting-cell nuclei migrated
into the hair-cell layer. This pattern is consistent with the first stages of transdifferentiation.
To test whether supporting cells were capable of giving rise to hair cells after they
had proliferated, we treated P21 utricles with TRULI and virally transfected the cultures
with Atoh1-RFP upon drug withdrawal. Demonstrating a capacity for transdifferentiation
into putative hair-cell precursors, many EdU- and Pou4f3-positive cells were observed
after Atoh1 transfection (Fig. S6D).
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Effects of TRULI on cardiomyocytes and Müller glia
Because the regenerative effects of activating Yap in organs such as the retina and heart
have been characterized extensively5,14,15,17, we investigated whether TRULI treatment is
effective in eliciting cellular proliferation in these contexts.
The proliferative capacity of cardiomyocytes in culture and the capacity of the heart
to regenerate decline sharply after birth5. To ascertain whether TRULI activates Yap and
induces regeneration, we exposed P0 murine cardiomyocytes to TRULI for 3 d. In control
cultures, protein blotting revealed high levels of phospho-Yap indicative of Hippo activity.
TRULI treatment reduced the proportion of phosphorylated Yap and induced
cardiomyocyte proliferation, as demonstrated by a significant increase in the percentage
of cells positive for the markers Ki67 and phosphorylated histone H3 (Fig. 6A-E).
Moreover, treated cells developed cytoskeletal rearrangements and protrusions and
decreased in size, phenotypes consistent with de-differentiation and proliferation,
respectively (Fig. 6F,G)43.
Yap activation may permit retinal regeneration in mammals by stimulating the
proliferation of Müller glial cells, progenitors with a capacity to differentiate into
photoreceptors and neurons17,44. To test whether TRULI induces the proliferation of
Müller glia, we used retinal organoids derived from human induced pluripotent stem cells.
As expected, Müller cells remained largely quiescent in control cultures. In organoids
treated for 5 d with 10 µM TRULI, however, Müller cells exhibited a robust increase in
proliferation (Fig. 6H-K).

Discussion
Most experiments demonstrating the regenerative effects of Yap activation in mammalian
tissues have used transgenesis, viral transfection, or indirect approaches such as
activation of G protein-coupled receptors by sphingosine-1-phosphate or epinephrine.
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Although these studies have provided proof-of-principle results, manipulation of Yap
signaling with small molecules represents a more feasible translational approach. In fact,
the only other published inhibitor of the Hippo pathway, XMU-MP-1, activates Yap
signaling and facilitates healing of the liver and intestinal epithelium after damage18. It is
noteworthy, however, that in our hands XMU-MP-1 did not promote supporting-cell
proliferation in the utricle. This result suggests that other enzymes function redundantly
to Mst kinases in the sensory epithelia. These likely include the Map4K kinases, which
activate Lats kinases in other contexts45. In fact, our RNA-sequencing data revealed that
Map4K2, Map4K3, and Map4K4 are all highly expressed in the adult murine utricle. To
our knowledge, no enzymes are broadly redundant to Lats1 and Lats2. Inhibition of Lats
kinases with TRULI might therefore provide an effective means of inactivating Hippo
signaling in a variety of tissues.
Re-entry into the cell cycle is only one component of regeneration; the daughter
cells must also assume their correct cell fates. Our data suggest that, in addition to
inducing proliferation, TRULI treatment leaves newly formed supporting cells in a plastic
state. After undergoing division, supporting cells re-enter G0 upon drug withdrawal, and
many cells shift their nuclei into the hair-cell layer and activate expression of characteristic
hair-cell genes; the pattern is strikingly similar to the regenerative response in nonmammalian vertebrates8. Because these cells can initiate transdifferentiation upon Atoh1
overexpression, combining Hippo inhibition with inhibition of Notch signaling or Atoh1
gene therapy might constitute an effective approach to restoring hair cells.
In contrast to the robust response in the adult murine utricle, the vast majority of
supporting cells in the neonatal cocTiktaalikhlea remained quiescent after 5 d of TRULI
treatment. A wave of transcriptional up-regulation of Cdkn1B, the gene encoding
P27Kip1, is known to control both the timing and the pattern of cell-cycle exit in the organ
of Corti46. This process seems absent from the utricle. Activation of Wnt signaling
promotes proliferation in the neonatal organ of Corti, but the effect primarily involves
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Kölliker's organ and the lateral Hensen's cells47,48,49,50. This pattern resembles that
observed after treatment with TRULI. To facilitate cell-cycle re-entry, the organ of Corti
might require a more prolonged exposure to proliferative stimuli or treatments that target
multiple signaling pathways.
Although pharmacological manipulation of the Hippo pathway might prove useful
in dealing with many human diseases, much remains unknown about the potential pitfalls
of Lats inhibition. In the context of the Hippo pathway Lats1 and Lats2 are considered
redundant, but each paralog also has unique functions such as estrogen-mediated
signaling and p53 regulation, respectively. Furthermore, Lats kinases and Yap have
ancient and conserved non-Hippo functions in spindle-assembly checkpoints and
cytokinesis51. TRULI also offers the ability to investigate these non-Hippo functions of
Lats kinases, and it would be prudent to understand the implications of Lats inhibition on
these pathways prior to therapeutic endeavors.
Another potential concern about Lats inhibition is oncogenic transformation. In this
regard the effect of systemic inhibition of Mst kinases is encouraging18: even after longterm administration, no oncogenic transformation was observed in mice treated with
XMU-MP-1. Moreover, the impact of Lats inhibition might be mitigated by local application
in isolated fluid compartments such as the endolymph of the inner ear, vitreous humor of
the retina, and pericardium of the heart. Finally, the relationship of Yap to cancer is
complex. Yap activation is a marker for poor prognosis in some cancers, but the opposite
is true in other instances52. Mutations of proteins in the Hippo pathway are rarely
causative of cancer, but are instead secondary to the molecular changes associated with
tumorigenesis3. In fact, activation of Yap through deletion of Lats kinases in certain
syngenic tumors decreases their progression and metastasis in immune-competent mice
by augmenting the immune response53.
In summary, TRULI is a potent, non-toxic, and reversible inhibitor of Lats kinases,
and thus a powerful tool for exploring the role of Hippo signaling in a variety of biological
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contexts. As expected on the basis of prior work, Yap activation with TRULI induces the
proliferation of murine neonatal cardiomyocytes in primary culture and of human Müller
glia in retinal organoids. Moreover, the sensory epithelia of the inner ear now join the list
of tissues amenable to Yap-mediated regeneration. In view of the ubiquity of these
effects, it is plausible that drugs related to this novel thiazolimine class will prove useful
in therapeutic contexts.

Materials and Methods
Animal care and strains
Experiments were conducted in accordance with the policies of the Institutional Animal
Care and Use Committees of The Rockefeller University, the University of Southen
Califiornia, and the Weizmann Institute of Science.
Swiss Webster mice were obtained from Charles River Laboratories. Sox2-CreER,

aMHC-Cre, and ROSA26-tdTomato mice were obtained from the Jackson laboratory.
Yapfl/fl (Zhang et al., 2010) were provided by Dr. Martin, Baylor College of Medicine.
Cardiac muscle cells were lineage-traced with tdTomato-fluorescent protein by
intercrossing aMHC-cre mice54, which exhibit highly efficiency recombination in
cardiomyocytes, with ROSA26-tdTomato mice55 that require Cre-mediated recombination
for expression. Both lines were maintained on a C57BL/6 background.
Chemical libraries
A total of 140,238 different compounds from a library at The Rockefeller University HighThroughput and Spectroscopy Resource Center were chosen by a quantitative estimate
of drug-likeness score56. The compounds originated in the following commercially
available libraries: ChemDiv (San Diego, CA), Enamine (Monmouth Junction, NJ),
BioFocus (Charles River, Wilmington, MA), ChemBridge (San Diego, CA), Specs
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(Zoetermeer, The Netherlands), Life Chemicals (Niagara, Canada), and AMRI (Albany,
NY). Compound stocks were stored in 384-well polypropylene plates at a final
concentration of 5 mM in DMSO at -30 ˚C.
High-throughput screen for small-molecule activators of nuclear Yap
Three human epithelial cell lines, one human embryonic kidney 293 line (HEK293T), and
two human mammary gland epithelia lines (MDA-MB and MCF 10A), were tested for the
screen. Of the three lines, only MCF 10A cells display a reproducible correlation between
the number of cells seeded and the number of cells adhered after 24h in culture and thus
were selected for the screen.
MCF 10A cells (ATCC CRL-10317) were cultured in a medium comprising
DMEM/F12, 5 % horse serum (Invitrogen 16050-122), 20 ng/L epidermal growth factor
(Millipore GF155), 0.5 mg/L hydrocortisone (Sigma H-0888), 100 ng/L cholera toxin
(Sigma C-8052), 10 mg/L insulin (Sigma I-1882), and antibiotic-antimycotic solution. Cell
cultures reached 100 % confluence at an approximate density of 3·105 cells per square
millimeter.
For the small-molecule screen, chemical-library plates were thawed at room
temperature and 0.1 μL of each compound was placed in a well of a 384-well assay plates
(Greiner Bio-One) containing 10 μL of MCF 10A culture medium (PerkinElmer Janus with
Nanohead). MCF 10A cells were then plated in 40 μL of MCF 10A culture medium to
achieve a final concentration of 10 µM for each compound and 0.25 % (vol/vol; 35 mM)
dimethyl sulfoxide. Negative (100 % confluent) and positive (25 % confluent) control wells
included an identical concentration of the DMSO vehicle.
After 24 hr incubation, the cells were fixed, washed thrice in PBS, and
immunolabeled for Yap. The nuclei were stained with 3 mM 4,6-diamidino-2-phenylindole
dihydrochloride (DAPI). The plates were imaged automatically with a 10X objective lens
on the ImageXpress XLS wide-field Micro reader (Molecular Devices, Sunnyvale, CA)
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with MetaXpress software (Molecular Devices). Using an empty plate to avoid out-offocus images, we configured a laser-based autofocus routine for automatic well-bottom
detection. We imaged DAPI and Yap conjugated to Alexa Fluor 488 with filter cubes for
respectively DAPI (excitation, 350-400 nm; emission 415-480 nm) and FITC (excitation,
460-505 nm; emission, 510-565 nm). The acquisition system was configured to image
one site per well. After the fluorescence of DAPI had been used to set the image-based
autofocus, the exposure time for each fluorophore was determined with a negative-control
well in which the fluorescence signal was set to 75 % of the camera’s maximal intensity.
An image-segmentation application from MetaXpress software was used to
automatically analyze the images. The number of cells was estimated by selecting an
average size and intensity level above the local background in the DAPI channel.
A built-in translocation module that measured the intensity movement from one
compartment to another was configured to determine the nuclear or cytoplasmic status
of the Yap. These measurements were acquired first for the positive and negative control
wells to determine an arbitrary threshold for the intensity ratio that characterized nuclear
translocation versus cytoplasmic retardation of Yap. The same threshold was then
applied to each well treated with a small-molecule to identify the substances that
increased the number of cells with nuclear Yap without affecting cell survival. Positive
controls were not used to normalize data, but to confirm whether the cells were healthy
and behaving as expected.
Images were stored in the MDCStore database and analyzed using MetaXpress
software (Molecular Devices). Output data were uploaded and analyzed using the CDD
Vault from Collaborative Drug Discovery (Burlingame, CA).
The compounds showing over 10 % Yap nuclear translocation and over 5,000 cells
per field were selected and the corresponding images were checked to verify the
phenotype. To determine half-maximal inhibitory concentrations, the selected compounds
were re-tested in concentration-response experiments by serially diluting by half for a total
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of ten dilutions to achieve assay concentrations ranging from 20 µM to 0.03 µM. IC50s
values were calculated by CDD software. Six compounds were confirmed in this
secondary screen.
Small-molecule Lats inhibitor
The

compound

N-(3-benzylthiazol-2(3H)-ylidene)-1H-pyrrolo[2,3-b]pyridine-

3-carboxamide (CAS number 1424635-83-5), of relative molecular mass 334.4 Da and
herein termed TRULI, was obtained from Enamine LLC (Z730688380, Monmouth
Junction, NJ).
Dissection and culture of inner-ear sensory epithelia
Internal ears were dissected from mice euthanized with fluothane and placed into ice-cold
Hank’s balanced salt solution (HBSS; Gibco14025-092)57.
Unless indicated otherwise, explanted cultures of the utricle and cochlea were
maintained in an incubator at 37 ˚C in the presence of 5 % CO2 and 95 % O2. The
complete growth medium comprised Dulbecco's modified Eagle medium with nutrient
mixture F-12 (DMEM/F12) supplemented with 33 mM D-glucose (Sigma G8644), 19 mM
NaHCO3 (Sigma S8761), 15 mM HEPES (Sigma H0887), 1 mM glutamine (Sigma
G8540), 5 mM nicotinamide (Sigma N0636), 40 µg/L epidermal growth factor (Sigma
E9644), 20 µg/L fibroblast growth factor (Sigma F5392), insulin-transferrin-selenite
solution (Sigma 11074547001), and antibiotic-antimycotic solution (Gibco 15240062).
For proliferation assays, utricles were cultured with 10 µM 5-ethynyl2¢-deoxyuridine (EdU) that was detected with click chemistry (Click-iT EdU imaging kit,
Thermo C10340).
Culture of epithelial cells
MCF 10A cells were cultured as described above. HEK293A cells were maintained in
DMEM (Gibco 11965-092), 10 % fetal bovine serum (Sigma F2442), and antibiotic-
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antimycotic solution. All cells were incubated at 37 ˚C in the presence of 5 % CO2 and
95 % O2.
Culture of primary cardiomyocytes
Cardiac muscle cells were lineage-traced with tdTomato-fluorescent protein by
intercrossing aMHC Cre mice54, which exhibit highly efficiency recombination in
cardiomyocytes, with ROSA26-tdTomato mice55 that require Cre-mediated recombination
for expression. Both lines were maintained on a C57BL/6 background.
Neonatal primary cardiac cultures were isolated from P0 pups with a neonatal
dissociation kit (Miltenyi Biotec,130-098-373) and homogenizer (gentleMACS). Cardiac
cultures were seeded in gelatin-coated wells coated with 0.1 % gelatin (G1393, Sigma)
in DMEM/F12 medium supplemented with 1% L-glutamine, 1 % sodium pyruvate, 1 %
nonessential amino acids, 1 % penicillin-streptomycin solution, 5 % horse serum, and
10 % fetal bovine serum. After culture in 5 % CO2 for 24 hr at 37 ˚C, the medium was
replaced for an additional 72 hr with bovine serum-free medium containing 0.1 % (vol/vol)
DMSO and, for experimental samples, 20 µM TRULI.
Culture of human pluripotent stem cells and retinal organoids
The WTC-11 line of induced pluripotent stem cells (Coriell Institute for Medical Research,
Camden, NJ) was maintained using standard methods. Human retinal organoids were
produced from these cells58. In three independent proliferation assays, five organoids
225-280 d of age per experimental condition were sampled in culture after incubation for
5 d in 10 µM TRULI and 10 µM EdU. The organoids used in the immunoblot analysis were
160-178 d of age and were incubated for 24 hr in 10 µM TRULI.
Immunohistochemistry of murine inner-ear sensory epithelia
Utricles were fixed in 4 % formaldehyde (Thermo 28906) for 1 hr at room temperature
and then blocked for 2 hr at room temperature with 3 % bovine serum albumin (BSA;
Jackson AB 2336846), 3 % normal donkey serum (Sigma-Aldrich D9663), and 0.3 %
Triton X-100 (Sigma 93443), in Tris-buffered saline solution (Thermo 28358).
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The primary antisera—goat anti-Sox2 (R&D AF2018), rabbit anti-myosin 7A
(Proteus 25-6790), mouse anti-Yap (SC-101199), rabbit anti-Sall2 (HPA004162), and
mouse anti-Pou4F3 (SC-81980)—were reconstituted in blocking solution and applied
overnight at 4 ˚C.
Samples were washed with phosphate-buffered saline solution supplemented with
0.1 % Tween 20 (Sigma-Aldrich), after which Alexa Fluor-labeled secondary antisera (Life
Technologies) were applied in the same solution for 1 hr at room temperature.
Nuclei were stained with 3 mM DAPI.
Immunofluorescence assays for cardiomyocytes
Cells were fixed in 4 % formaldehyde for 10 min with shaking at room temperature,
permeabilized for 5 min with 0.5 % Triton X-100 in PBS, and blocked for 1 hr at room
temperature with 5 % BSA in PBS containing 0.1% Triton X-100. The cells were labeled
overnight at 4 ˚C with the primary antibodies anti-Ki67 (1:200, 275R, Cell Marque) and
anti-phosphorylated histone 3 (1:200, 9701, Cell Signaling) for. After three washes with
PBS, samples were labeled for 1 hr at room temperature with fluorescent secondary
antibodies (Abcam) followed by 10 min of DAPI staining for nuclear visualization. After
three washes in PBS, cells were imaged with a Nikon Eclipse Ti2 microscope.
Immunofluorescence imaging of retinal organoids
Fresh frozen sections were permeabilized and blocked in a humidified chamber for 1 hr
at room temperature with 3 % horse serum in PBS with 0.3 % Triton X-100. The slides
were exposed for 2 hr to primary antibodies diluted in the same solution. Anti-Sox-9
(1:100, Rb Cell Signaling 82630) was used to mark Müller cells. Slides were washed three
times with PBS. Secondary antisera (Alexa-Fluor 488 and 647) diluted 1:10,000 in the
serum solution were added for 1 hr at room temperature followed by two washes with
PBS. Labeling for 30 min at room temperature (Apply Click-iT Invitrogen Alexa Fluor 555
C10338) was followed by a wash with PBS. After incubation with DAPI (1:10,000 in PBS)
for 5 min and the application of mounting solution, sections were imaged by confocal
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microscopy with a Zeiss LSM 700 system with a 20X/0.8 NA objective lens with a pinhole
size set at the first Airy disc.
Protein immunoblotting and quantification
MCF 10A, HEK293 cells, retinal organoids, and utricles were lysed on ice in
radioimmunoprecipitation assay buffer solution (RIPA; BP-115-5x) with protease
inhibitors (Halt Protease Inhibitor Cocktail, Thermo 87786). Utricles were additionally
sonicated thrice at low power for 10 s, with breaks of 20 s with the samples kept on ice
between sonications After lysates had been scraped and centrifuged at 10,000 RPM for
10 min at 4 ˚C, the supernatants were immediately subjected to electrophoresis or stored
at -80 ˚C.
A standard immunoblotting protocol was used with the following specifications. A
4-12 % bis-tris gel (Thermo NP0322) was used to resolve the proteins in 5 mg of each
sample. The proteins were transferred to a nitrocellulose membrane (BioRad 1704156)
and blocked for 1 hr at room temperature (Rockland MB-070). After primary antibodies
had been reconstituted in the same solution, the membrane was incubated overnight at
4 ˚C. After three 5 min washes at room temperature in tris-buffered saline solution with
0.05 % Tween 20, a secondary antibody conjugated to horseradish peroxidase (Millipore)
was applied in the same solution for 1 hr at room temperature before activity was detected
(SuperSignal West Pico PLUS, Thermo 34580). Images were acquired with an
iBrightFL1000 system.
We used at a dilution of 1:1000 primary antibodies directed against Yap
(sc-101199), phospho-Yap S127 (CST 4911), Lats1 and Lats2 (Abcam, ab70565),
phospho-Lats1 S909 (CST 9157), Mst1 (CST 3682), Mob1 (CST 13730), phospho-Mob1
T35 (CST 8699), tubulin (Sigma T6793), and GAPDH(Abcam ab8245).
Cultured cardiomyocytes were lysed using RIPA supplemented with protease and
phosphatase inhibitors (1:100, Sigma). Lysates were prepared and 30 µg protein of each
sample was fractionated by gel electrophoresis in tris-glycine acrylamide gels, and
subsequently transferred to a PVDF membrane. Following 1 hr blocking at room
temperature, membranes were incubated with the following antibodies against
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phospho-Yap at s112 (1:1000, 13008, cell signaling), Yap (1:2000, NB110-58358, Novus)
and Rabbit anti GAPDH (1:8000, PLA0125, Sigma) for 1 hr at room temperature.
Following two washes in tris-buffered saline solution containing 0.1 % Tween 20,
membranes were incubated with horseradish peroxidase anti-rabbit or secondary
antibodies (Jackson). The signal was detected by super-signal west pico plus
chemiluminescence kit (34580, Thermo-Fisher).
Immunoblots were quantified through measurement of band intensity with Fiji59.
The final value of each band’s intensity was normalized by the sum of all the bands’
intensities. Significances from Student’s t-tests are denoted as follows: *, p < 0.05; **,
p < 0.01; ***, p < 0.001; ****, p < 0.0001. Unless otherwise indicated, error bars denote
standard errors of means (SEMs).
Imaging of Yap nuclearization and quantification of proliferation
Confocal imaging was conducted with a confocal microscope enhanced with structured
illumination (VT-iSIM, VisiTech International Ltd.).
For quantification of Yap nuclearization, for each condition two fields of supporting
cells were imaged at 60X from two utricles. Using CellProlifer60, we masked Sall2-positive
nuclei and measured the intensity of their labeling. The same mask was then applied to
the Yap channel and the intensity of labeling was measured. The ratio of the Yap to the
Sall2 intensity was calculated for each condition in 680 cells after TRULI treatment and
570 cells for DMSO controls.
For quantifying the proliferation of supporting cells, we imaged utricles at 60X, then
assembled the images into a composite tiling (Grid Collection Stitching, Fiji). The maximal
values in z-stacks were projected to display the entire supporting-cell layer of the sensory
epithelium, excluding connective tissue and the surrounding epithelium. Using
CellProlifer60, we counted the number of EdU-positive nuclei. Alternatively, EdU- and
Sox2- doubly positive nuclei were counted using Multi-point Tool in ImageJ.
Images acquired from neonatal cardiac cultures were analyzed using ImageJ
software by thresholding for cardiomyocytes according to endogenous tdTomato
fluorescence. Thresholded figures were carefully and manually separated by fine lines to
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de-cluster cells in case they touch, basing on original images, following by measurements
of area and solidity.
Images acquired from retina organoids were analyzed with CellProfiler60. Masks
were created for all the Sox9-positive nuclei, and the percentage of EdU- and
Sox9-positive nuclei were counted.
In vitro kinase assay
The in vitro kinase assay (HTRF KinEASE-STK S1, CisBio 62ST1PEB) was optimized to
the linear reaction range of the enzymes Lats1 (Carna 01-123) and Lats2 (Carna 01-124).
Reactions were conducted with 10 µM STK1 substrate and 10 µM ATP, unless otherwise
indicated. For the ATP-shift assay, ATP was also used at concentrations of 50 µM and
250 µM. Lats1 was employed at a concentration of 200 pg/µL and Lats2 at 50 pg/µL,
unless otherwise indicated. For the assay in which Michaelis-Menten constants for ATP
were determined, each enzyme was at a concentration of 62.5 pg/uL, and Lats1 ran for
30 min, and the Lats2 ran for 20 min, all at room temperature. The DMSO concentration
was maintained at 0.5 % (vol/vol) throughout all experiments, and a Janus 384 MDT
(PerkinElmer) equipped with a 50 nL Pintool (V&P Scientific, Inc.) was used to add the
compounds dissolved in DMSO to the reaction. The enzyme, substrate, ATP, and TRULI
were combined in a low-volume 384-well plate and shaken for 50 min at room
temperature, unless otherwise indicated. The reaction was stopped by adding the
detection reagents, which were prepared at an 8:1 biotin:streptavidin ratio, and shaken
for 60 min at room temperature. All reactions were conducted in triplicate and a Synergy
NEO (Biotek) was used to detect the signal.
Cellular kinase assay
HEK293A cells were plated overnight in 96-well culture plates at a density of 50,000 cells
per well in the medium described above. To start the assay, new serum-free medium with
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various concentrations of the compound was added to the cells, which were then
incubated for 30 min at 37 ˚C. The DMSO concentration was kept at 0.1 % (vol/vol), and
all experiments were performed in triplicate.
Total Yap and phospho-Yap were detected according to the two-plate protocol for
adherent cells (Total Yap Cellular Kit, Cisbio 64YATPEG; phospho-Yap [Ser127] Cellular
Kit, Cisbio 64YapPEG). The signal was detected by Synergy NEO (Biotek).
Modeling of enzyme structure
Lats1 and Lats2 are in the AGC kinase family, which also contains kinase sub-families
such as Ndr and Rock33. In Homo sapiens, Lats1 has an overall sequence identity of
51.7% with Lats2, of 42.2% with Ndr2, and of 39.9% with Rock1. Owing to the presence
of the classic kinase hinge-binding azaindole motif in TRULI, we focused on the kinase
domain and analyzed the ATP-binding site in order to generate a homology model. To
define this site we used the 36 kinase-domain residues defined by Huang et al.61. We
show an alignment of these ATP-binding site residues for 62 human AGC kinases
(Table S1) and the identities of these residues between Lats and the other AGC kinases
(Table S2). It is worth noting that the sequence identity between Lats1 and Lats2 in the
ATP-binding site is 97.2%, with only a single conservative difference (lysine to arginine).
To generate a homology model of the kinase domain we selected a complex of
Rock1 bound to an azaindole thiazole inhibitor (PDB ID: 5KKS)62 . This complex was
selected because the sequence identity between Lats1 and Rock1 in the ATP binding site
is 72.2% and the bound inhibitor shares an azaindole group with TRULI. Athough the
resolution of the structure is a modest 0.33 nm (3.3 Å), the electron density within the
ATP-binding site is good and allows the conformation of the ligand and the amino acid
side-chains to be determined unambiguously. The protein structure was downloaded from
the Protein Databank, selenomethionines were changed to methionines, and missing
sidechains were added with Schrodinger’s Preparation Wizard. This program was also
used to fix the orientations of the asparagine, glutamine, and histidine residues as well
as the protonation states of all ionizable residues. Heteroatomic species such as water
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molecules, buffer solvents. and ions were removed and the complex was energy
minimized with a restraint of the all-atom root-mean-square distance to 0.03 nm (0.3 Å).
The homology model was generated from residues 705-1043 of Lats1 with a knowledgebased model in Schrodinger’s Advanced Homology tool. Chain B of ROCK1 was used as
the template and the azaindole thiazole inhibitor was retained.
The resulting homology model was then used for molecular docking with
Schrodinger’s Glide SP63. The Glide grid was generated around the azaindole thiazole
inhibitor in the ATP-binding site with T845 as a rotatable group. TRULI was prepared
using Schrodinger’s Ligprep and docked using Schrodinger’s Glide SP using default input
parameters. The Glide SP docking score was -39 kJ/mol (-9.4 kcal/mol), corresponding
to a binding affinity of approximately 130 nM.
The ligand’s azaindole group is predicted to bind to the hinge region as expected,
whereas the ligand’s thiazolimine group contacts D846 in the DFG loop and the ligand’s
benzyl group contacts the C-terminal F1039, which forms the active-site tether in many
AGC kinases64.
Although the numbers assigned to the amino-acid residues of various proteins
elsewhere in the text refer to the murine products, those in the present paragraph
reference the human proteins.
RNA sequencing and data analysis
Supporting cells were isolated by fluorescence-activated cell sorting from the utricles of
Lfng-EGFP mice as described previously65. The total RNA was extracted using QuickRNA MicroPrep kit (Zymo Research) and stored up to 2 weeks at -80 ˚C. RNA samples
were then processed for library preparation with QIAseq FX Single Cell RNA Library Kit
(Qiagen) and the quality of the library was confirmed using a Bioanalyzer (Quick Biology
Inc.). A minimum of two biological replicates were collected for each condition, and at
least 20 million 150 base-paired-end reads were sequenced for each replicate. Reads
were mapped to GRCm38/mm10 genome assembly using STAR66. Differentially
expressed genes were identified by DESeq267. Only the protein coding sequences were
considered for FPKM calculation. For data visualization, the ggplot2 package was used
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(H. Wickham, Springer New York, 2009). Principal components analysis was performed
with pcaExplorer68 on the 1000 genes whose differential expression was most significant.
Adenoviral gene transfer
The AdEasy Adenoviral Vector System (Agilent) was used to create adenoviral vectors
containing the full-length coding sequence of murine Atoh1 under the control of a
cytomegalovirus promoter. To permit the identification of infected cells, we also included
sequences for an internal ribosome-entry site and for RFP. Viral particles were amplified
and purified by CsCl-gradient centrifugation followed by dialysis (Viral Vector Core
Facility, Sanford Burnham Prebys Medical Discovery Institute). Utricles were infected in
200 μL of culture medium with 10 μL of virus at a titer of 1010 pfu/mL. Ad-RFP virus
(Vector Biolabs) at the same titer were used as a control.

Supplemental Information
Supplemental information can be found in the attached file.
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Figure 1. High-throughput screen for activators of Yap translocation to nuclei
(A) A schematic diagram demonstrates the strategy for identification of compounds that
promote the nuclear transit of Yap, thus reversing the exclusion characteristic of contact
inhibition. (B) The number of MCF 10A cells rises almost linearly with their confluency.
(C) Nuclear localization of Yap falls systematically with increasing confluency in MCF 10A
cultures. (D) Immunolabeling of Yap (red) demonstrates nuclear localization of the protein
in a positive-control (subconfluent) culture and in a negative-control (confluent) culture.
Treatment of a confluent culture with a representative hit compound promotes extensive
movement of Yap into nuclei.
See also Figure S1.

106

Figure 2. Activation of Yap and proliferation of supporting cells
(A) A timeline depicts the pattern of the experiments shown in the indicated subsequent
panels. Treatment with TRULI is initiated at the outset. (B) TRULI exposure drives Yap
into the nuclei of utricular supporting cells. (C) In vitro exposure to TRULI for 5 d elicits
proliferation of supporting cells, as measured by the incorporation of EdU. Verteporfin, an
inhibitor of the Yap-Tead interaction, drastically reduces this effect. (D) The nuclear
localization of Yap is quantified as a ratio to the constitutively expressed protein Sall2
(p < 0.0001 by an unpaired, two-tailed t-test, n = 570 control nuclei and 680 treated
nuclei). (E) The number of EdU-positive cells per utricle increases with TRULI (p = 0.021
by an unpaired, one-tailed t-test, control n = 2, TRULI n = 3), but the effect is blocked by
verteporfin (p = 0.028 by an unpaired, one-tailed t-test, n = 2). (F) Conditional deletion of
Yap by tamoxifen administration to SOX2-CreER Yapfl/fl (Yap CKO) animals at P1, 7 d or
14 d prior to explantation, decreases the number of Sox2 (red) and EdU (white) doubly
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positive

supporting

cells

compared

to
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littermates.

(G) Quantification of the number of EdU-positive cells in panel F demonstrates that
decrease in supporting-cell proliferation is statistically significant (Student’s t-tests; n = 3
for wild-type control and Yap CKO at 7 d; n = 4 for TRULI treatment; n = 6 for Yap CKO
at 10 d and TRULI).
See also Figure S2.
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Figure 3. ATP-competitive inhibition of Lats kinases.
(A) Protein immunoblotting discloses that treatment of MCF 10A cells with TRULI leaves
Hippo signaling intact through the activation of Lats kinases, but that Yap phosphorylation
is greatly diminished. (B) Serum starvation of HEK293A cells in the presence of TRULI
also demonstrates Lats activation but suppression of Yap phosphorylation. (C) TRULI
comprises a thiazolimine backbone with two substituents: a benzyl group and a
7-azaindole hinge-binding motif. (D) In a simulated structure of TRULI in the predicted
ATP-binding site of Lats1, the protein is displayed as a ribbon with heavy atoms in atomcolored wire representation with grey carbons. TRULI is displayed in an atom-colored,
ball-and-stick representation. Aspartate 846 is positioned to bind the thiazolimine group
and phenylalanine 1039 to interact with the benzyl moiety. (E) An in vitro assay of Lats1
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kinase activity shows that the IC50 for TRULI increases with the ATP concentration, from
0.2 nM at 10 µM, to 4.3 nM at 50 µM, and to 80 nM at 250 µM, demonstrating that the
compound is an ATP-competitive inhibitor. (F) A kinase assay conducted with serumstarved HEK293A cells indicates an EC50 of 510 nM for TRULI. Starvation does not
significantly deplete the total amount of Yap. In panels E and F, error bars represent SEs.
See also Figures S3 and S4.
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Figure 4. Gene-expression changes evoked treatment in supporting cells by TRULI.
(A) For three experiments, principal-component analysis was performed on RNAsequencing data obtained from supporting cells after 5 d of treatment with TRULI or from
control samples. (B) A volcano plot visualizes the differentially expressed genes
(| log2(fold change) | > 1; padj<0.05). Genes upregulated after TRULI treatment compared
to control are labeled in red and those downregulated in blue. (C) Gene-ontology (GO)
analysis performed with DAVID software demonstrates that the terms associated with the
cell cycle are the most enriched in the genes upregulated by TRULI, whereas the terms
associated with stress are more enriched in the control gene set. A full list of differentially
expressed genes identified using DEseq2 is available on request. (D) For three
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experiments, a heatmap demonstrates the relative expression levels of 140 cell-cycle
genes differentially expressed between control and TRULI-treated supporting cells (false
discovery rate < 0.01) in comparison to E17.5. Highly expressed genes are shown in red
and genes with relatively low levels of expression are depicted in blue. (E) Cell-cycle
genes of the G1-S transition of the cell cycle are significantly upregulated by TRULI to the
levels found in E17.5 supporting cells (p < 0.001 by a Wilcoxon signed-rank test).
(F) Markers of the G2-M transition are likewise upregulated (p < 0.001 by a Wilcoxon
signed-rank test). (G) For three experiments, the heatmap demonstrates the relative
expression levels of 79 Yap-target genes differentially expressed between control and
TRULI-treated supporting cells (false discovery rate < 0.01) in comparison to E17.5
embryonic levels. (H) The expression of Yap-target genes is upregulated in response to
TRULI to the levels found in E17.5 supporting cells (p < 0.05 by a Wilcoxon signed-rank
test). (I) In contrast, the relative level of expression for genes associated with cell death
remains unchanged between controls, TRULI-treated, and E17.5 supporting cells
(p > 0.05 by a Wilcoxon signed-rank test).
See also Figure S5.
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Figure 5. Supporting-cell plasticity after TRULI treatment.
(A) A volcano plot visualizes the genes differentially expressed after 5 d of TRULI
treatment followed by 5 d drug withdrawal (| log2(fold change) | > 1; padj < 0.05). The
subset of hair-cell genes most upregulated after TRULI treatment compared to control
are labeled. (B) Gene-ontology analysis performed with DAVID software demonstrates
that the terms associated with hair-cell differentiation and function are the most enriched
in the genes upregulated by TRULI. A full list of differentially expressed genes identified
using DEseq2 is available on request. (C) In the representative examples of whole mount
utricular explants after 5 d of TRULI treatment followed by 5 d drug withdrawal,
immunolabeling for Pou4f3 (green) and Myo7a (red) depicts hair cells. New sensory
receptors formed from proliferated supporting cells are identified by EdU-incorporation
(white) and are found only after TRULI treatment. Nuclei are labeled with DAPI. (D) The
total number of hair cells per utricle does not change after TRULI treatment (p > 0.05 by
a Student’s t-test; n = 4 for controls and n = 5 for TRULI treated animals).
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See also Figure S6.

Figure 6. Proliferation of cardiomyocytes and Müller cells.
(A) A protein immunoblot indicates that TRULI decreases the phosphorylation of Yap in
neonatal cardiomyocytes in vitro. (B) Quantification of the data in panel A shows the
significance of the effect (p = 0.008 by an unpaired, two-tailed t-test, n = 4).
(C) Immunofluorescent labeling discloses that 3 d of TRULI treatment elevates the cellcycle marker Ki67 (arrowheads) in cardiomyocytes. Scale bars, 50 µm. (D) Quantification
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again reveals significant effects for Ki67 (p = 0.001 by an unpaired, two-tailed t-test,
n = 4). (E) A marker of mitotic initiation, pH3, is similarly elevated by treatment (p = 0.026
by an unpaired, two-tailed t-test, n = 4). (F) The cardiomyocyte solidity, an index of
cellular shape, decreases significantly after treatment, an effect consistent with
de-differentiation (p < 0.0001 by an unpaired, two-tailed t-test, n = 232 control cells and
197 TRULI-treated cells). (G) TRULI treatment reduces the areas of cardiomyocytes,
another sign of mitosis (p < 0.0001 by an unpaired, two-tailed t-test, n = 231 control cells
and 197 TRULI-treated cells). (H) A protein immunoblot indicates that 24 hr of treatment
with TRULI decreases the phosphorylation of Yap in Sox9-marked Müller cells of human
retinal organoids. (I) A bar graph documents the effect observed in panel H (p = 0.024 by
an unpaired, two-tailed t-test, n = 3). (J) After 5 d of TRULI treatment, EdU labeling shows
a substantial increase in cellular proliferation. (K) A bar graph quantifies the result of
panel J in three experiments (p < 0.0001 by an unpaired, two-tailed t-test, n = 15 control
organoids and 16 TRULI-treated organoids).
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Figure S1. Screening for activators of Yap translocation into nuclei. Related to Figure 1.
(A) The adherent properties of three human epithelial-cell lines—one embryonic kidney line (HEK
293T) and two mammary-gland lines (MDA-MB and MCF 10A)—were tested. Only MCF 10A cells
display a reproducible correlation between the number of cells seeded and the number of cells
adhered after 24 hr. (B) In a representative example of cell survival in ten 384-well plates
screened in the assay for nuclear translocation of Yap, the plate indexes are indicated on the
x-axis and the total number of cells detected in each well of each plate is indicated on the y-axis.
Purple lines demonstrate the average mean (M) and one standard deviation (SD) below the mean
of the number of cells detected in each negative control well (blue dots) of each of the ten plates
screened. Red dots represent sub-confluent positive control wells; black dots represent each well
treated with a compound. The substances that decreased the number of cells over one SD were
eliminated owing to toxicity. (C) In the same ten 384-well plates analyzed in panel B, the
percentage of cells with nuclear Yap was determined using MetaXpress software. Only one in a
thousand compounds increased this value more than one standard deviation (SD; purple line)
above the mean value determined for the negative controls (M; purple line).
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Figure S2. Lack of Yap activation by the Mst inhibitor XMU-MP-1. Related to Figure 2.
(A) Six utricles per condition were treated for 24 hr with 10 µM TRULI or XMU-MP-1 to assess
effects on the amount of phospho-Yap by comparison to control conditions. (B) Quantification of
band-intensity ratios for phospho-Yap and total Yap in the immunoblot of panel A shows that
XMU-MP-1 does not reduce the fraction of phosphorylated Yap. (C) When adult mouse utricles
were explanted and cultured with EdU (white) and either TRULI or varying concentrations of
XMU-MP-1, the latter caused no increase in proliferation. Nuclei are stained with DAPI (blue).
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Figure S3. Proliferative response in the cochlea after treatment with TRULI. Related to
Figure 2. (A) No hair-cell loss is observed after 5 d of treatment of the P1 organ with 10 µM
TRULI. Only the most lateral rows of Hensen’s cells re-enter the cell cycle after the treatment.
(B) TRULI elicits robust proliferation of Sox2-positive cells in Kölliker’s organ, as measured by the
incorporation of EdU.
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Figure S4. Optimization and further results of in vitro kinase assay. Related to Figure 3.
(A) In order to perform assays at an appropriate ATP concentration, we established the MichaelisMenten constants for Lats1 (Km = 9.4 µM) and Lats2 (Km = 7.6 µM). (B) A kinetic assay for Lats1
was used to determine the optimal signal-to-noise ratio within the linear range of product
formation. Enzyme concentrations are indicated in micrograms per liter. (C) The corresponding
assay was performed for Lats2. (D) The half-maximal inhibitory concentration of TRULI against
Lats2 was IC50 = 0.2 nM.
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Figure S5. Cell-cycle exit after TRULI withdrawal. Related to Figure 4. (A) As shown in the
timelines to the left, utricles were explanted and cultured for 5 d in the presence of TRULI; EdU
was then added at various times. In first top row, when EdU was present throughout the 5 d period
of culture, extensive proliferation occurred in the striolar region. The second row shows that
proliferation was still heavier when EdU was presented during the day following TRULI exposure.
The third row indicates that proliferation declined during the second day after TRULI withdrawal.
The fourth row demonstrates that proliferation fell to nearly the background level when EdU was
provided three days after the withdrawal of TRULI. (B) A bar graph quantifies the number of EdUpositive nuclei per sensory epithelium in the foregoing experiments. Each datum is an average
from two utricles.
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Figure S6. Cell-cycle exit and hair cell differentiation after TRULI withdrawal. Related to
Figure 5. (A) RNA-sequencing analysis demonstrates that the genes active in G2-M are
downregulated to the control levels in P21 supporting cells 5 d after TRULI withdrawal.
(B) S-phase genes are similarly downregulated. (C) Genes known to be targets of theYap-Tead
complex are also downregulated. (D) To assess whether new hair cells can be formed after TRULI
treatment, P21 utricles that had been treated with TRULI for 5 d were cultured for two days to
allow cell-cycle exit, then transfected with adenovirus carrying Atoh1. The cultures were cotreated with EdU to permit lineage tracing of supporting cells that had undergone cell division in
the presence of TRULI. After 5 d of Atoh1 expression, many EdU-positive supporting cells
displayed high levels of Pou4f3 protein, demonstrating the potential of supporting cells to
transdifferentiate.
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Table S1. Alignment of residues at the ATP-binding sites of AGC kinases. Related to
Figure 3. These 36 residues define the ATP-binding pockets of 62 kinases, but do not represent
continuous sequences.
LATS1
LATS2
NDR1
NDR2
ROCK1
ROCK2
RSKL2
SgK494
PDK1
RSK4
RSK1
RSK3
RSK2
p70S6K
p70S6Kb
MSK1
MSK2
YANK2
YANK3
YANK1
PKCi
PKCz
SGK2
SGK
SGK3
PKN3
PKN2
PKN1
AKT1
AKT2
AKT3
PKCt
PKCd
PKCe
PKCh
PKCg
PKCb
PKCa
BARK2
BARK1
RHOK
GPRK7
GPRK6
GPRK5
GPRK4
MAST3
MAST4
MAST2
MAST1
CRIK
MASTL
DMPK1
MRCKb
DMPK2
MRCKa
PKG2
PKG1
PRKX
PRKY
PKACg
PKACb
PKACa

LGIGAFGEVAKVRLFVMDYIPGGDMMSDKDNLTDFG
LGIGAFGEVAKVKLFVMDYIPGGDMMSDKDNLTDFG
IGRGAFGEVAKVKMLIMEFLPGGDMMTDKDNLSDFG
IGRGAFGEVAKVKMLIMEFLPGGDMMTDKDNLSDFG
IGRGAFGEVAKVQLMVMEYMPGGDLVNDKDNLADFG
IGRGAFGEVAKVQLMVMEYMPGGDLVNDKDNLADFG
VQDPATGGTMKSSGPHLNLLTPARLPSDHGNLTYFG
VAKGSFGTVAKHSLIMCSYCSTDLYSLDKENLTDFG
LGEGSFSTVAKVKLFGLSYAKNGELLKDKENLTDFG
LGQGSFGKVAKVKLLILDFLRGGDVFTDKENLTDFG
LGQGSYGKVAKVKLLILDFLRGGDLFTDKENLTDFG
LGQGSFGKVAKVKLLILDFLRGGDLFTDKENLTDFG
LGQGSFGKVAKVKLLILDFLRGGDLFTDKENLTDFG
LGKGGYGKVAKVDLLILEYLSGGELFMDKENMTDFG
LGKGGYGKVAKVELLILECLSGGELFTDKENMTDFG
LGTGAYGKVAKVTLLILDYINGGELFTDKENLTDFG
LGTGAYGKVAKVTLLILDYVSGGEMFTDKENLTDFG
IGKGSFGKVAKVNLMVVDLLLGGDLRYDKDNLTDFN
IGKGSFGKVAKVNLMVVDLLLGGDLRYDKDNLTDFN
IGKGSFGKVAKVNLMVVDLLLGGDLRYDKDNLTDFN
IGRGSYAKVAKVGLFVIEYVNGGDLMFDKDNLTDYG
IGRGSYAKVAKVGLLVIEYVNGGDLMFDKDNLTDYG
IGKGNYGKVAKVGLFVLDYVNGGELFFDKENLTDFG
IGKGSFGKVAKVGLFVLDYINGGELFYDKENLTDFG
IGKGSFGKVAKVGLFVLDFVNGGELFFDKENLTDFG
LGRGHFGKVAKLSLFVTEFVPGGDLMMDKDNLADFG
LGRGHFGKVAKVNLFVMEYAAGGDLMMDKDNLADFG
LGRGHFGKVAKVNLFVMEYSAGGDLMLDKDNLADFG
LGKGTFGKVAKTALFVMEYANGGELFFDKENMTDFG
LGKGTFGKVAKTALFVMEYANGGELFFDKENMTDFG
LGKGTFGKVAKTSLFVMEYVNGGELFFDKENMTDFG
LGKGSFGKVAKTHMFVMEYLNGGDLMYDKDNLADFG
LGKGSFGKVAKTHLFVMEFLNGGDLMYDKDNLADFG
LGKGSFGKVAKTQLFVMEYVNGGDLMFDKDNLADFG
LGKGSFGKVAKTQLFVMEFVNGGDLMFDKDNLADFG
LGKGSFGKVAKTQLFVMEYVTGGDLMYDKDNMTDFG
LGKGSFGKVAKTQLFVMEYVNGGDLMYDKDNMADFG
LGKGSFGKVAKTQLFVMEYVNGGDLMYDKDNMADFG
IGRGGFGEVAKVCMFILDLMNGGDLHYDKANLSDLG
IGRGGFGEVAKVCMFILDLMNGGDLHYDKANLSDLG
LGKGGFGEVAKVSLLVMTIMNGGDIRYDKENLSDLG
LGKGGFGEVAKVSLLVMSLMNGGDLKFDKENLSDLG
LGKGGFGEVAKVSLLVLTLMNGGDLKFDKENLSDLG
LGKGGFGEVAKVNLLVLTIMNGGDLKFDKENLSDLG
LGKGGFGEVAKVSLLVLTIMNGGDLKFDKENLSDLG
ISNGAYGAVAKVSMMVMEYVEGGDCATDKDNLTDFG
ISNGAYGAVAKVSMMVMEYVEGGDCATDKDNLTDFG
ISNGAYGAVAKVSMMVMEYVEGGDCATDKDNLTDFG
ISNGAYGAVAKVGMMVMEYVEGGDCATDKDNLTDFG
VGCGHFAEVAKPQLLVMEYQPGGDLLSDKENLVDFG
ISRGAFGKVAKVHLLVMEYLIGGDVKSDKDNLTDFG
IGRGAFSEVAKTQLLVMEYYVGGDLLTDKDNLADFG
IGRGAFGEVAKTALLVMDYYVGGDLLTDKDNLADFG
IGRGAFGEVAKTTLLVMDYYAGGDLLTDKDNLADFG
IGRGAFGEVAKTTLLVMDYYVGGDLLTDKDNLADFG
LGVGGFGRVAKVKLMLLEACLGGELWSDKENIVDFG
LGVGGFGRVAKVRLMLMEACLGGELWTDKENIVDFG
VGTGTFGRVAKIRLMLMEYVPGGELFSDKENLTDFG
MGTGTFGRVAKIRLMLMEYVPGGELFSDKENLTDFG
LGMGSFGRVAKVKLLVMEYVPGGEMFSDKENLTDFG
LGTGSFGRVAKVRLMVMEYVPGGEMFSDKENLTDFG
LGTGSFGRVAKVKLMVMEYVPGGEMFSDKENLTDFG
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Table S2. Percentage sequence identity for the 36 residues of the ATP-binding site
between Lats1 and Lats2 and AGC kinases. Related to Figure 3. In this and the subsequent
two tables, colors identify different sub-families of the AGC kinase family.

AGC kinase
LATS1
LATS2
PKACb
PKN2
PKN1
ROCK1
ROCK2
PKACg
PKACa
PKCe
PKCg
NDR1
NDR2
MASTL
MRCKb
DMPK2
MRCKa
SGK
PKN3
PKCt
PKCd
PKCh
PKCb
PKCa
MSK1
MSK2
CRIK
DMPK1
PRKX
PRKY

Identity
to Lats1
(%)
100.0
97.2
75.0
72.2
72.2
72.2
72.2
72.2
72.2
69.4
69.4
69.4
69.4
69.4
69.4
69.4
69.4
66.7
66.7
66.7
66.7
66.7
66.7
66.7
63.9
63.9
63.9
63.9
63.9
63.9

Identity
to Lats2
(%)
97.2
100.0
72.2
72.2
72.2
72.2
72.2
75.0
75.0
69.4
69.4
72.2
72.2
69.4
69.4
69.4
69.4
66.7
66.7
66.7
66.7
66.7
66.7
66.7
63.9
63.9
63.9
63.9
61.1
61.1

RSK4
RSK3
RSK2
YANK2
YANK3
YANK1
PKCi
SGK2
SGK3
AKT1
AKT2
AKT3
RHOK
GPRK7
MAST3
MAST4
MAST2
MAST1
RSK1
PKCz
GPRK6
GPRK5
GPRK4
PDK1
BARK2
BARK1
PKG1
p70S6K
PKG2
p70S6Kb
SgK494
RSKL2
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61.1
61.1
61.1
61.1
61.1
61.1
61.1
61.1
61.1
61.1
61.1
61.1
61.1
61.1
61.1
61.1
61.1
61.1
58.3
58.3
58.3
58.3
58.3
55.6
55.6
55.6
55.6
52.8
52.8
50.0
44.4
27.8

63.9
63.9
63.9
61.1
61.1
61.1
61.1
61.1
61.1
61.1
61.1
61.1
61.1
61.1
61.1
61.1
61.1
61.1
61.1
58.3
58.3
58.3
58.3
58.3
55.6
55.6
52.8
52.8
55.6
50.0
44.4
27.8

Table S3. Target enzymes binding more potently than LATS1. Related to Figure 3. Of 314
kinases in a binding panel, these enzymes bound 1 µM TRULI more strongly than did Lats1 or
Lats2. The assay did not test for functional inhibition.
Kinase

Affinity

CLK4
PRKCQ

102.191
99.155

CDC7

99.093

DMPK
CDC42BPA

97.919
97.161

HIPK3

95.798

HIPK2
PRKACB

94.205
92.922

CLK2

92.819

GSK3B
PRKCH

92.698
90.416

CDK19

90.205

PKN2
CDK8

89.660
88.778

PRKX

88.131

BMP2K
HIPK1

86.274
86.064

DYRK1A

85.826

PASK
ROCK2

85.771
84.111

CDC42BPG

83.657

PAK4
DYRK1B

83.440
81.514

TGFBR2

81.311

LRRK2
ROCK1

81.277
79.232

PRKG2

79.109

CLK1
PRKCD

78.062
77.995

PKN1

77.735

MAP4K4
DAPK3

77.535
77.096

TAOK1

76.404

LATS2
MAP3K7

74.882
74.047

LATS1

73.903
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Table S4. Half-maximal inhibitory concentrations (IC50s) of TRULI for selected kinases.
Related to Figure 3.

Kinase

IC50 (nM)

PKA

60

PKCepsilon

14

ROCK1

88

NDR1

1000
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